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Abstract 
A mathematical model is proposed in this thesis for the 
control mechanism of free fatty acid-glucose metabolism in healthy 
individuals under resting conditions. The objective is to explain in 
a consistent manner some clinical laboratory observations such as 
glucose, insulin and free fatty acid responses to intravenous injection 
of glucose, insulin, etc. Responses up to only about two hours from the 
beginning of infusion are considered. The model is an extension of 
the one for glucose homeostasis proposed by Charette, Kadish ~nd 
Sridhar (Modeling and Control Aspects of Glucose Homeostasis. Mathe-
matical Biosciences, 1969). It is based upon a systems approach and 
agrees with the current theories of glucose and free fatty acid metab-
olism. The description is in terms of ordinary differential equations. 
Validation of the model is based on clinical laboratory data available 
at the present time. Finally procedures are suggested for systematically 
identifying the parameters associated with the free fatty acid portion 
of the model. 
iv 
TABIE OF CONTENTS 
ABSTRACT 
I INTRODUCTION 
II THE .METABOLIC PROCESSES AND CONTROL 
2.1. 
2.2. 
2 .3. 
2.4. 
2.5. 
Introduction 
The Biochemical Aspects 
The Physiological Aspects 
Hormonal Control of Metabolism 
Glucose Homeostasis and FFA Metabolism 
III THE PROPOOED MODEL FOR FFA-GWCOOE .METABOLISM 
3 .1. 
3.2. 
3.3. 
3.4. 
3.5. 
3.6. 
Introduction 
The Proposed Model. 
3.2.l.. The Glucose Model. 
3. 2 • 2 • Models for Hormone Controllers 
3.2.3. The FFA Model 
The Basic Building Blocks 
The Results 
A T,ypical Example of the Proposed Model 
The Choice of Parameter Values 
IV ESTIMATION OF PARA.METERS OF THE PROPOOED FFA MODEL 
v 
4.1. 
4.2. 
4.3. 
4.4. 
4.5 
Introduction 
The General Approach 
The FFA Model Equations 
The Identification Problems 
A Feedback Control Experiment 
CONCLUSIONS 
5.1. Future Efforts 
5. 2. Concluding Remarks 
APPENDIX 
LIST OF REFERENCES 
~ 
iii 
1 
5 
5 
5 
10 
14 
15 
25 
25 
26 
26 
34 
37 
48 
53 
70 
79 
99 
99 
100 
102 
104 
134 
141 
141 
153 
154 
156 
v 
LIST OF ABBREVIATIONS 
ADP 
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I. INTRODUCTION 
Mathematical modeling of biological and physiological pro-
cesses is an area of active research at the present time. Mathematical 
representation has been attempted for several physiological processes 
such as respiration, systemic circulation, motor functions, glucose 
homeostasis etc., to mention a few. It is now well-known that the 
mechanism by which the body maintains the concentration of blood glucose 
at a specified level is a finely regulated control system - hence the 
well-accepted term glucose homeostasis. It is a feedback control system 
in which the desired value of the controlled quantity, namely the blood 
glucose level, is a constant. The primary task of the control mechanism 
is to maintain the actual blood glucose concentration at its desired 
value in the presence of disturbances. The control is effected by spe-
cific hormones released by the endocrine system in response to deviations 
from the equilibrium state. 
Several authors have attempted modeling of the control mech-
anism of glucose homeostasis. An excellent review of the literature 
appears in a recent thesis by Charette~lIzF With one exception, the 
models proposed for glucose homeostasis do not explicitly include the 
1 
effects of FFA • It is important to emphasize the dominant role of 
FFA in the supply of energy and in the regulation of blood sugar. It 
is estimated that approximately 5Cf'/o of total respiration is derived 
from FFA oxidation under basal conditions. The important role of FFA 
in the endogenous supply of glucose by the liver is becoming increasingly 
1 Abbreviation for free fatty acids. 
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evident. Shames(3) presents a simple linear representation for the 
effects of FFA on blood glucose regulation based on the hypothesis of 
glucose-fatty acid cycle proposed by Randle etKa1~4 F 
In this thesis a nonlinear dynamic model is proposed for the 
control mechanism of FFA-glucose metabolism in normal healthy individuals 
under resting conditions. Models for FFA metabolism both under resting 
conditions and during exercise have been reported in the literature~ RI SITF 
These are linear and are based on tracer studies. They mainly provide 
information regarding the various pathways and turnover rates of FFA 
under steady state conditions. For a review of compartment models for 
lipid metabolism the reader is referred to a recent article by Nome 
Baker~pF The modeling efforts reported herein are quite different from 
those based on tracer studies. The main objective is to explain in a 
consistent manner with the aid of a mathematical model clinical laboratory 
observations such as glucose, insulin and FFA responses (up to 2 hours) 
to rv1 infusions of g1ucose, insulin etc. Attention is focussed on the 
changes in plasma concentrations of glucose, FFA, insulin and other hor-
2 
mones due to disturbances introduced into the metabolic plant. These are 
variables that can be directly measured. Only short-term responses such 
as the ones mentioned above are considered. Accordingly, the model 
proposed here does not include the effects of substrates such as amino 
acids and 'IG3 and other hormones such as glucocorticoids and 
1 
2 
3 
Abbreviation for intravenous. 
The word metabolic plant refers to the aggregate of all metabolic 
processes taking place in the body. 
Abbreviation for triglyecerides. 
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thyroxin. These substrates and hormones do not play any significant 
role in the 2-hour responses that are dealt with in this thesis. Inputs 
such as stress, exercise and exposure to cold are omitted for the sake 
of simplicity. Only IV inputs are considered; this eliminates the 
complexity introduced by the inclusion of gastrointestinal tract. 
The approach taken here is a systems one. The model is 
comprised of interconnected subsystems, each subsystem representing 
one·or more physiologic processes. The subsystems are modeled based on 
known stimulus-response characteristics. They are interconnected in 
a logical way based on current understanding of the metabolic pro-
cesses. Each subsystem may include several biochemical reactions and 
these may be taking place simultaneously in several organs or locations 
in the body. It is emphasized that the model includes the major phys-
iological quantities of interest and is intended to reproduce the gross 
effects of FFA-glucose metabolism. It is a systems representation ob-
tained by properly interconnecting the relevant subsystems, even though 
some of them may be grossly approximated. Once we obtain a systems 
model, the mathematical representations of the subsystems can be re-
fined as we understand more about the pertinent biochemical reactions. 
Val i•tat.ion of the model is based on clinical laboratory data available 
at the present time. 
The modeling efforts reported here started with the aim of 
establishing a methodology for the investigation of human metabolic 
control systems. Bodily metabolic processes are enormously complex 
in nature. The substrates, enzymes and controls that participate are 
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so large in number that it is beyond the capability of any present-day 
computing machine to handle simultaneously all the pertinent equations, 
assuming that one can describe mathematically all the biochemical 
reactions and physiologic functions that are involved - an extremely 
difficult task, if not impossible! Even if it is possible, it is highly 
doubtful whether one can gain futher understanding of the metabolic 
processes by describing them in all their infinite details. On the 
other hand, overly simplified models (a second order differential 
equation, for example) are of questionable utility. The systems approach 
takes a central position between the above two extremes. A systems 
mod.el aims at a simple representation that does not obscure the basic 
facts; yet it is made detailed enough to explain at once several clin-
ical findings. The physiologic aspects are borne in mind throughout. 
The systems approach seems particularly suitable for analyzing complex 
systems such as bodily metabolic systems. 
The author does not certainly claim to have constructed the 
ultimate mod.el that will explain every aspect of FFA-glucose metabolism. 
The author's model is only one of the evolutionary series of mod.els to 
be developed, tested and improved. Although the results presented ar~ 
meagre, the limited success gives credence to the methodology. Methods 
and tools for analyzing higher dimensional nonlinear systems have be-
come available only recently. These methods and tools combined with 
clinical tests such as tolerance tests and techniques such as tracer 
studies should undoubtedly lead to a better understanding of the metab-
olic processes and their use in alleviating disease states. 
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II. THE METABOLIC PROCESSES AND CONTROL 
2.1. Introduction. 
In this chapter some pertinent biochemical and physiological 
aspects of metabolism in general will be summarized. Special attention 
will be devoted to glucose homeostasis and FFA metabolism. Although 
the term metabolism in its broadest sense includes all physical and 
chemical processes involved in life activities it is commonly employed 
to denote the processes by which food substances - carbohydrates, 
proteins and fats - are converted into energy. We will use it in the 
latter sense throughout. The discussion presented here is extremely 
brief and is included so as to provide the necessary background material 
for the presentation of the proposed model in the next chapter. The 
metabolism of carbohydrate, protein and fat has been reviewed and dis-
cussed in great depth in several text books and articles~9-l4 F The 
reader is referred to these publications for further details. A brief 
account appears also in Charette's thesis( 2) and reference 9. 
2.2. The Biochemical Aspects. 
All living organisms constantly require energy for sustaining 
life and activity. All living cells are equipped with extremely complex 
mechanisms for transforming the chemical energy inherent in the mole-
cular bonds of food substances into other forms of energy such as heat 
or mechanical work. The ultimate products of combustion are carbon 
dioxide and water and the principal mechanism is oxidation. Most of 
the energy derived from the substances being burned is not immediately 
released as heat during oxidation but is retained as chemical energy. 
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In other words the body stores energy in chemical form by transforming 
the food substances into other compounds. The stored energy is freed 
whenever there is demand. The precise means by which chemical energy 
is retained as such and not immediately released remains as one of the 
mysteries of life. 
Central to the mechanism of storage and release of chemical 
energy of the body is a high energy compound called adenosine triphos-
phate, known universally by its initials ATP. This ubiquitous nucle-
otide is the principal intracellular carrier of chemical energy from 
the energy-yielding oxidation of food substances to those processes or 
reactions of the cell which do not occur spontaneously and can proceed 
only if chemical energy is supplied. Processes such as diffusion occur 
spontaneously and do not require external supply of energy; whereas 
mechanical work such as muscular contraction, electrical activity and 
synthesis of many chemical compounds are energy-dependent. Part of 
the energy of the food is conserved during oxidation by formation of 
ATP from adenosine diphosphate (ADP). The chemical energy of ATP is 
then utilized in the energy-dependent cellular processes, degrading ATP 
to ADP. The ATP-ADP system serves as a linking agent, so to speak, 
between the high-energy phosphate donors, formed during oxidation of 
food substances, and the low-energy phosphate acceptors. It is the 
primary energy carrier system of the cell. 
We shall now briefly discuss some salient features of inter-
mediary metabolism. The term intermediary metabolism refers to the 
intermediate chemical reactions in the intracellular transformation 
of foodstuffs within the body. Figure l depicts a highly simplified 
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Figure 1. General Scheme of Intermediary Metabolism. Broken lines represent 
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scheme of intermediary metabolic pathways. Ingested food consists of 
carbohydrates, proteins, fats and a small fraction of minerals and 
vitamins. The principal end products of digestion are monosaccharides 
including glucose, amino acids, FFA and chylomicrons consisting mainly 
of TG. In the cells glucose is promptly phosphorylated to form glucose-
6-phosphate, a hexosephosphate compound. It is then either catabolized 
or converted into glycogen, the stored form of glucose. The process of 
glycogen formation is called glycogenesis and that of glycogen break-
down is known as glycogenolysis. The catabolism of glucose can proceed 
via either the Embden-Meyerhof pathway or the hexosemonophosphate shunt. 
Glucose is converted into pyruvic and lactic acids through the Embden-
Meyerhof pathway. The process is know as glycolysis. The reactions 
of this pathway are anaerobic, i.e., they do not require oxygen. On the 
other hand, the reactions of the hexosemonophosphate shunt are aerobic. 
For this reason it is also known as the direct oxidative pathway. Re-
latively a large number of ATP moleucles are produced through this 
pathway of glucose catabolism. 
The citric acid cycle (also known as Krebs cycle or tricar-
boxylic acid cycle) is the common pathway for oxidation to co2 and 
H20 of all the food substances. It requires oxygen and does not 
function under anaerobic conditions. The main entry into the cycle is 
through acetyl CoA1, but pyruvic acid and a number of amino acids 
also enter it after conversion into some of its intermediates such as 
oxaloacetic acid, for example. 15 mols of ATP can be generated from 
1 Abbreviation for acetyl coenzyme A. 
-~ 
1 mol of pyruvic acid in the citric acid cycle. 
Triglycerides, the major end products of digestion of fats, 
are made up of fatty acids and glycerol (3 mols of fatty acids bound to 
1 mol of glycerol). When hydrolyzed they liberate their contituent fatty 
acids and glycerol. The process is termed lipolysis. The reverse process, 
namely synthesis of triglycerides, is called lipogenesis. Glycerol is 
converted first into a triosephosphate and then into either glucose or 
co2 and H20. The fatty acids are broken down to acetyl CoA which 
then enters the citric acid cycle. The energy yield of this process 
is large. 38 mols of ATP can be generated by catabolism of 1 mol of a 
six-carbon fatty acid through the citric acid cycle. Acetyl CaA 
serves also as precursor for cholesterol production. 
It should be noted that interconversions among amino acids, 
fatty acids and glucose are possible via acetyl CaA and intermediates 
of the citric acid cycle. Of the various interconversions that are 
possible the most important· one is the production of glucose from non-
carbohydrate sources, especially from amino acids. The process is 
known as gluconeogenesis. 
The biochemical pathways indicated in the simplified scheme 
of Figure 1 are present in all the cells of the body to a greater or 
smaller extent. However, the rate at which a particular reaction or a 
group of reactions can take place in a particular cell in the body 
depends upon the function of the organ to which the cell belongs. For 
example, the storage of glucose in the form of glycogen takes place to 
a large extent only in liver, kidney and muscle. It is not a major 
pathway for glucose in adipose tissue~1R F The processes gluconeogene-
-lO-
s is and glucose production from glycogen are exlcusive to liver and 
kidney. Another example is ketogenesis (production of ketones) which 
takes place only in liver. It is well-known that all biochemical 
reactions occuring in living organisms are enzyme-catalized reactions. 
Evidently for a given reaction to proceed the cell must have the nec-
essary enzymatic machinery available to it. Muscle is not capable of 
producing glucose from glycogen because it lacks the needed enzyme, 
glucose-6-phosphatase. Ketogenesis is caused in liver due to an enzyme 
called deacylase which other cells do not possess. A common feature of 
all the cells of the body is the citric acid cycle. All cells are 
endowed with the enzymes required for the reactions of the citric acid 
cycle. 
2.3. The Physiological Aspects 
A diagrammatic summary of the interrelated processes associated 
with the metabolism of carbohydrate, protein and fat is depicted in 
Figure 2. The diagram is an attempt to systematize the known physiologic 
facts as a first step toward the eventual derivation of a detailed met-
abolic control model using the systems approach. It represents what may be 
the desired minimal complexity for obtaining meaningful results with a 
dynamic metabolic control model. The fat, carbohydrate and protein 
loops are shown together along with the couplings involved. The dia-
gram includes all the major metabolic processes and physiologic vari-
ables. The lumped processes are indicated by arrows and the variables 
are shown inside rectangles. In addition to the couplings shown, the 
three major loops are coupled through the hormones that control the 
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various metabolic processes. Hormones are subtances secreted by partic-
ular organs into the general circulation which carries these sub-
stances to their sites of action where they regulate the rates of 
specific processes without contributing any significant amount of energy 
or matter to the tissues. Hormonal effects are not indicated in Figure 
2. It should be noted that the diagram is the exact dual of an engi-
neering representation in which the variables are indicated by arrows 
and the processes inside rectangles. 
Glucose, the principal product of carbohydrate digestion and 
the dominant circulating blood sugar, is the major source of energy in 
the absorptive phase following ingestion of food. A small amount of 
fat is oxidized, but most of it is stored in adipose tissue as 'l'G. 
Amino acids are either converted back into protein or catabolized by 
deamination and further oxidation. Liver and kidney are the major 
sites of metabolism of amino acids absorbed after digestion. Excess 
carbohydrate is stored as glycogen, but most of it is converted into 
'l'G by lipogenesis and stored. The pathway is via pyruvic acid and 
acetyl CaA (see Figure 1). The storage of glycogen is very small in 
adipose tissue~1S F Triglycerides are a more compact form of energy 
storage. They take up less volume per calorie of stored energy. 
An important pathway for glucose in muscle is anaerobic 
glycolysis and the consequent production of lactic acid. This happens 
when the supply of oxygen is insufficient as, for example, following 
exercise. Under such conditions the muscle lactic acid concentration 
increases and it diffuses into the blood stream to be transported to 
the liver. In the liver it is either catabolized or converted into 
-13-
glucose by gluconeogenesis. A smaller amount of pyruvic acid also 
undergoes the same process. The cycle, plasma glucose - muscle 
glucose - muscle lactic acid - plasma lactic acid - liver lactic acid -
liver glucose - plasma glucose, is known as the Cori cycle. 
As the postabsorptive phase progresses the oxidation of fatty 
acids becomes the predominant source of energy. Under fasting conditions, 
adipose tissue provides the fatty acids by breaking down its stores of 
TG. One molecule of TG, when broken down, gives rise to three molecules 
of FFA1 and one molecule of glycerol. The glycerol fraction released 
cannot be reutilized in adipose tissue to any significant extent. It 
is carried by the blood stream to the liver where it is either converted 
into glucose or oxidized to co2 and H2o. Apparently all tissues of 
the mammalian organism so far examined can oxidize fatty acids complete-
2 ly to co2 and H20. However the CNS depends solely on glucose for its 
oxidative needs. It oxidizes glucose at a very nearly constant rate 
under most circumstances. Under fasting conditions, the glucose needs 
of the CNS are met chiefly by the liver which produces glucose by both 
glycogenolysis and gluconeogenesis. 
Increased supply of fatty acids to the liver induces ketogene-
sis, resulting in the production of ketones - acetone, acetoacetic and 
~-hydroxybutyric acid5. Since the liver cannot easily metabolize these 
substrates, they are released into the blood stream and are carried to 
1 
2 
Tri-, di- and monoglycerides are fatty acids in esterified form -
esterified with glycerol. Unesterified fatty acids are called 
free fatty acids. 
Abbreviation for central. nervous system - the brain and the spinal 
cord. 
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extrahepatic sites (chiefly muscle) where they are readily utilized. 
Liver produces and releases also 'lG for utilization elsewhere in the 
body. There are thus five major substrates available to the tissues 
of the body for oxidative purposes. They are listed in Table 1 along 
with their turnover rates and oxygen requirements. (l7) 
mM/min Substrate Major Sites of Oxidation Oxidized 
: Brain and CNS 0.33 Glucose 
FFA _,Co 2 Liver and Extrahepatic tissues 0.22 
FFA _, Ke tones Liver o.o4 
Ketones ..... Co2 Extrahepatic tissues 0.16 
Amino acids Liver 
-
Glycerides All tissues 
-
All Total Body 
Table 1. Substrate utilization rates by man 
under basal conditions. 
2.4. Hormonal Control of Metabolism 
Oxygen 
Consumption 
(ml/min) 
45 
ll4 
6 
15 
) 70 
250 
Substrates and their amounts that are transported and met-
abolized in the various organs of the body vary depending on the 
nutritional state, the level of exercise, the termperature of the 
surroundings, the psychic factors and so forth. Means must therefore 
be provided for the controlled storage and release of energy. The 
processes associated with the storage, release, transport and utiliza-
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tion of metabolic fuels are under the precise control of the endocrine 
system (ductless glands which discharge their products into the general 
circulation). The endocrine glands, through the production and release 
of hormones regulate the various processes so as to maintain the homeo-
stasis of the organism under varying environmental conditions. 
The endocrine system is close.1¥ linked, both developmental.1¥ 
and functional.1¥, to the nervous system. In fact, the two are often 
spoken of as a unit, the neuroendocrine system. In some respects the 
endocrine system acts more or less independent.1¥; in others it is so 
close.1¥ related to the nervous system that it may be considered func-
tional.1¥ as an extension of it. This intimate connection between the 
two systems allows psychic influences to mod:ify hormonal activities. 
There are at least six hormones (four hormones and two 
hormone groups) that have dominant effects upon the metabolic processes 
in humans. They are listed in Table 2 along with their molecular 
weights, normal fasting plasma1 concentrations, sources, stimuli and 
important effects on carbohydrate, protein and fat metabolism. Of 
these, glucocorticoids and thyroxin do not play any significant 
role in the short-term responses reported in this investigation. 
2.5. Glucose Homeostasis and FFA Metabolism 
The normal fasting level of glucose in plasma ranges from 
80 mg/lOOml to 100 mg/lOOml (80 - 100 mg%) in healthy individuals. 
Under normal fasting conditions this level is regulated in the classical 
1 The fluid portion of blood excluding the cellular elements, 
principal.1¥ the red blood cells. 
TABLE 2. Major hormones that control the metabolism of carbohydrate, fat and protein. 
t = Increase; + = Decrease 
TYPICAL FASTING 
iA.PPROXIMATE PLASMA LEVEL OR IMPORTANT EFFECTS ON MEI'ABOLISM 
MOLECULAR SECRETION RATE PRIMARY OF CARBOHYDRATE, FAT, AND 
NAME WEIGHT IN NORMAL HUMANS SOURCE STIMULI PROTEIN (18-22) 
1. Insulin 6000 15 µU/mi a-cells of i Hyper- Uptake of glucose by liver, muscle 
pancreas glycemia and adipose tissue t 
Muscle uptake of amino acids and 
I protein synthesis t Lipolysis + 
Auguments lipogenesis 
2. Glucagon 
I 
3450 o.4 ng/mi a-cells of Hypo- I Hepatic glycogenolysis t 
pancreas glycemia Gluconeogenesis t 
Proteolysis t* 
Insulin secretion t 
3.Catecholamines 
(i)Epinephrine 183.2 0.1 ng/mi Adrenal Hypo- Glycogenolysis in both 
medulla glycemia; liver and muscle t 
Physiologic Lipolysis t 
stress Insulin secretion + 
(ii)Norepin- 170 o.4 ng/mi Adrenal Physiologic Lipolysis t 
ephrine medulla; stress; Insulin secretion + 
Sympathetic Emotional 
nerve endgs. stress 
l 
I 
..... 
0\ 
I 
TABLE 2. (Continued) 
4. Growth hormone 21500 2 ng/mt Anterior Hypo- Lipolysis t 
pituitary glycemia Protein Synthesis t 
5.Glucocorticoids Adrenal Corti co- Gluconeogenesis t 
(i) Cortisol 329 20 mg/day Cortex tropin Proteolysis t from Ketogenesis t 
(ii) Cortico- 346 3 mg/day anterior 
sterone pituitary 
6.Thyroxin 776.9 80 µg/day Thyroid Thyrotropin Basal metabolic rate t 
from Plasma cholesterol level ~ 
anterior Hepatic glycogenolysis t 
pituitary Gluconeogenesis t 1-:' 
Proteolysis t 
Actions are interrelated to those 
of c atechola.mines 
*Refers to catabolism of proteins. 
-18-
control system sense, i.e., the level is maintained constant to within 
a small error of the order of + 2 mg%. Liver plays a central role in 
this regulatory process. Tissue utilization depletes plasma glucose 
which is replenished by the liver through glycogenolysis and gluconeogene-. 
sis. In a normal 70 kg. man with a liver mass of approximately 1.8 kg. 
the maximum liver glycogen stores amount to about 125 gm. of glucose. 
Assuming a basal glucose turnover of 150 mg/min, time taken to deplete 
125) 1000 4 the liver glycogen stores completely = 150 0 = l hr. approximately. 
The fact that liver glycogen is never depleted completely indicates 
that the above figure is an overestimate and underscores the importance 
of gluconeogenesis under fasting conditions. 
The major precursors of gluconeogenesis are: glycerol, amino 
acids, lactic and pyruvic acids. Glucose is produced from the latter 
two under anaerobic conditions through the Cori cycle (see page 13). 
Infusion of epinephrine also can cause this by its glycogenolytic action 
on muscle and the consequent increase of plasma lactic and pyruvic 
acids;( 23) whereas glucagon enhances gluconeogenesis from amino acids~ O4 F 
Under fasting conditions the chief precursors of gluconeogenesis are 
amino acids. The amount of glucose contributed by glycerol is small. 
The basal glycerol turnover rate is around 0.3 rmnoles/min;( 25 ) if all of 
this is converted into glucose it can contribute a maximum of only 
about 30 mg/min of glucose - 20% assuming a basal glucose turnover of 
150 mg/min. 
There is an im~ediate rise in plasma glucose concentration 
following r:v administration of glucose. After an oral load, maxi-
mum plasma level of glucose is attained in about 30 minutes in normal 
subjects. As the glucose level in plasma rises, the net output 
-19-
of glucose from liver decreases and the liver becomes a net sink 
for plasma glucose at an absolute concentration of about 150 mg%~ OS F 
Some amount of glucose is excreted in the urine when the absolute level 
exceeds 180 mg%. Until this level is reached the glucose filtered by 
ihe kidney from circulation is essentially reabsorbed. Increased levels 
of glucose stimulate the secretion of insulin from pancreas. Thus there 
is a concomitant rise in plasma insulin levels. The basic peripheral 
action of insulin is to promote the transport of glucose across the 
cell membrane. Adipose tissue is known to be highly sensitive in this 
respect. In addition to increasing the uptake of glucose, insulin in-
hibits lipolysis in adipose tissue and thus brings about a decrease in 
the supply of FFA and consequently in the level of FFA in plasma. A 
decreased supply of FFA results also from esterification of fatty acids. 
The essential pathways of glucose in adipose cell are indicated in 
Figure 3. 
Under hypoglycemic conditions, the plasma glucose level is 
below nominal. Hypoglycemia can be induced by injection of insulin, for 
example. The accelerated rate of peripheral uptake of glucose results 
in a loss of plasma glucose. Simultaneously decreased rates of 
lipolysis lower. the plasma FFA levels. Epinephrine, glucagon and Gtt1 
secreted in response to low levels of blood sugar tend to oppose the 
action of insulin. Epinephrine and glucagon enh:1nce the endogenous 
supply of glucose by accelerating the rates of glycogenolysis and glu-
coneogenesis. Lipolysis is stimulated resulting in an increased outflow 
1 Abbreviation for growth hormone. 
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of FFA from adipose tissue. Equilibrium is thus restored by the action 
of the so-called hyperglycemic and lipolytic agents - chiefly epinephrine, 
glucagon and GH. 
Adipose tissue is the organism's major reservoir of metabolic 
energy. By definition, it is composed of aggregates of fat cells 
located throughout the body at specific sites. Fat cells are now known 
to be metabolically highly active with a large blood flow in relation 
to active mass, important sympathetic innervation and both nervous and 
hormonal regulation. The primary functions of these cells are the 
storage of fat mainly in the form of 'lG and the release of FFA, a 
readily transportable source of energy, into the blood stream. The 
key reactions that govern the flow of FFA into and out of adipose 
tissue stores are 'lG breakdown and formation of 'lG from fatty acids 
and a-glycerophosphate. The latter is derived glucose (see Figure 3). 
It has now been confirmed that these two processes, lipolysis and 
esterification, go on continuously even at steady state~ OTF Net 
mobilization of FFA occurs if either the rate of breakdown is increased 
or the rate of production is decreased. Net deposition of 'lG occurs 
if the steady state is disturbed in the opposite direction. 
Breakdown of 'lG gives rise to FFA and glycerol. The process 
is inhibited by insulin and enhanced by lipolytic hormones such as 
catecholamines and GH. As mentioned earlier, most of the glycerol re-
leased is transported to the liver where it enters gluconeogenic path-
ways. The FFA are either re-esterified to 'lG in adipose tissue or enter 
the blood stream and are carried as FFA-albumin complexes. The 
amount of re-esterification depends upon the availability of glucose to 
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adipose tissue, Glucose is converted partly into a-glycerophosphate 
which is essential for esterification of fatty acids and partly into 
fatty acetyl CoA. a-glycerophosphate combines with fatty acetyl CoA, 
formed from both glucose and FFA, to yield 'I\} (see Figure 3). 
Adipose tissue is known to be the only endogenous source of 
plasma FFA. A large portion of FFA released into the blood stream is 
assimilated into the liver and the rest into other tissues (chiefly 
muscles). In both liver and muscle FFA are either oxidized to co2 and 
H20 or stored as 'I\} after esterification for latter use. A fraction of 
'I\} formed in the liver is released into plasma as lipoproteins 
proteins combined with lipid (see Appendix for concentration and com-
position of plasma lipoproteins). Ketones - acetoacetic and ~-hydrox­
ybutyric acids - are produced in the liver as a result of partial oxida-
tion of FFA. These ketones are either utilized by extrahepatic tissue 
for oxidation or excreted in the urine. 
There does not seem to be any homeostatic regulation of 
plasma FFA level as in the case of plasma glucose concentration. The 
p!..a.sma sugar level returns to normal in about ii hours after an IV 
administration of glucose and in about 3 hours after an oral glucose 
load. It takes much longer period of time for the establishment of 
steady state of plasma FFA level after a disturbance. Under fasting 
conditions the concentration of FFA in plasma increases slowly but 
steadily. Intake of food containing normal amounts of carbohydrate 
brings it down due to both increased re-esterification of fatty acids 
and decreased lipolysis in adipose tissue. The body begins to utilize 
more glucose and less FFA. 
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The role of amino acids is rather minor relative to glucose 
and FFA in the minute-to-minute supply of energy. Under basal conditions 
they supply only about 15% of the caloric needs. However they are the 
chief procursors for gluconeogenesis during fasting. Apparently FFA are 
necessary for the biochemical reactions involved in the conversion of 
1 
amino acids into glucose to proceed. Thus FFA seem to be responsible 
for the stimulation of gluconeogenesis in the liver under fasting 
d •t• 2 con i ions. A prompt decrease in the level of FFA in plasma following 
ingestion of glucose would then be expected to result in diminished 
rates of gluconeogenesis. Liver ceases to produce glucose and even 
becomes a net sink for glucose depending on the amount ingested. 
The switch-over from fat to carbohydrate following intake of 
food is accomplished with the aid of insulin. This ubiquitous hormone 
is essential for the utilization of glucose by many tissues in the 
body. Muscle and adipose tissue are known to be highly sensitive to 
the action of insulin. If sufficient amount of insulin is not secreted 
following administration of glucose, the entry of glucose into these 
tissues is severely impaired. Consequently the FFA accumulated in 
adipose tissue due to increased lipolysis during fasting are not re-
esterified. Also, since the supply of insulin is lacking lipolysis 
is not diminished. Furthermore gluconeogenesis is not stopped. Thus 
both glucose and FFA levels remain hjgh in the absence of insulin. 
l 
2 
FFA provide the needed hydrogen. 
Some authors( 2S, 29) 
0
view that gluconeogenesis is directly con-
trolled by insulin rather than by FFA and that increased rates 
of glucose production under fasting conditions are triggered by 
low levels of insulin alone • 
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There are plenty of substrates in the blood but the tissues have no 
means of utilizing them. This is the situation in diabetes mellitus 
and it clear~ indicates the important role of insulin in the minute-to-
minute regulation of energy storage and release. 
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III. THE PROPOSED MODEL FOR FFA-GLUCOSE METABOLISM 
3.l. Introduction. 
Mathematical modeling is concerned with establishing reasonable 
mathematical representations relating the inputs or stimuli to the outputs 
or responses, both of which are often defined intuitively. The first 
matter for consideration in modeling is to decide as to the kind of des-
cription that is appropriate for the phenomenon of interest. The most 
common representation for metabolic control systems such as glucose homeo-
stasis is in terms of ordinary differential equations. The choice implies 
subjective hypotheses and is greatly influenced by their use in classical 
control theory. The differential equation description of stimulus-re-
sponse relations often introduces intermediate variables called states. 
From a mathematical point of view the choice of states is not unique. 
However, this does not lead to ambiguities in the stimulus-response re-
lations. In biological applications the choice of states can be made 
unique by requiring that they represent biologically meaningful entities. 
In control system terminology the metabolic plant is a multi-
loop, multi-input-multi-output control system. For our purposes we shall 
define as outputs all those quantities that are directly available for 
measurement. Thus the plasma concentrations of substrates such as glu-
cose, FFA, amino acids etc., and hormones that control the metabolic 
processes are outputs of the plant. If lymphatic cannulation is perform-
ed, interstitial fluid concentrations would also be outputs. In addition 
there are other outputs such as the amounts of glucose, nitrogen, etc., 
excreted in the urine, the volume of oxygen inhaled, the volume of co2 
exhaled and so forth. Intravenous or oral admininstration of the 
various substrates and hormones and pharmacological agents such 
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as tolbutamide, nicotinic acid, etc., constitutes one class of inputs 
to the plant. Stress, exercise and exposure to cold or heat constitute 
another class of inputs. 
Starting from the general scheme shown in Figure 2 and using 
as few basic analytical building blocks as possible, a mathematical 
model for the dynamics of FFA-glucose metabolism has been constructed. 
It incorporates nonlinearities such as saturation effects and threshold 
phenomena that are inherent in the metabolic processes. It is intended 
to explain quantitatively the short-term (up to 2 hours) responses of a 
normal subject to IV inputs of glucose, insulin and other hormones and 
some meaningful combinations of these. The description is in terms of 
ordinary differential equations (nonlinear). Some salient features of 
the model are: 
(i) It includes the effects of four hormones, namely, insulin, 
epinephrine, glucagon and growth hormone. 
(ii) It includes gluconeogenesis as a function of plasma FFA con-
centration. 
(iii) It includes the effects of FFA metabolism on glucose uptake 
by muscle. 
3.2. The Proposed Model. 
3.2.1. The Glucose Model. 
Charette has suggested three different models for glucose 
homeostasis in normal humans based on the systems approach~ O F The glucose 
model included in this thesis is a modified version of his refined 
four hormone control model. It is depicted in Figure 4. In the dis-
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cussion to follow we shall restrict our attention to the modifications 
that have been made. The reader is referred to Section 3.7 of Charette's 
thesis for further details. 
(i) Perhaps the most significant modification is the inclusion of 
gluconeogenesis which is assumed to be stimulated by plasma FFA con-
centration. Gluconeogenesis is one of the major processes through 
which the glucose loop is coupled to the lipid and protein loops. The 
choice of plasma FFA level as the stimulus is supported by several 
pieces of evidence reported in the literature. Evidence suggesting the 
importance of FFA presentation in minute-to-minute glucose production 
by the liver has been discussed by Cahill etKal~ PoF Based on experi-
ments with rat liver, Walter etKa1~ PlF have postulated that fatty acids 
are not only the main energy supply for gluconeogenesis but that they 
also play a decisive role in stimulating this process. 
The increased gluconeogenesis observed in fasting and in 
diabetes is associated with increased mobilization and oxidation of 
fatty acids. It has been suggested that stimulation of gluconeogenesis 
might result from accelerated hepatic catabolism of fatty acids~P OIPPF 
It would therefore seem more reasonable to assume gluconeogenesis to be 
stimulated by liver uptake of FFA for oxidation. However, since the 
liver uptake of FFA increases with plasma FFA concentration the latter 
serves the purpose equally well in so far as the gross effects of FFA 
on glucose metabolism are concerned. Furthermore, identification of 
parameters associated with gluconeogenesis is facilitated if we assume 
that this process is stimulated by plasma level of FFA rather than by 
some other related quantity that is not readily available for measurement. 
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Such considerations dictate the choice whenever alternatives are available. 
The idea is to make the model as simple as possible, yet consistent with 
known physiologic facts. 
The mechanisms of regulation of gluconeogenesis are not clear. 
Contrary to the assumption that FFA stimulate gluconeogenesis, Seyffert 
etKal~wpF noticed a significant increase in plasma insulin and a fall in 
hepatic glucose output of normal dogs when they increased plasma FFA to 
levels found during prolonged starvation. Exton and Park( 34 ) in their 
in vitro perfusion studies on rat liver found no correlation between the 
rates of ketogenesis resulting from fatty acid oxidation and gluconeogene-
sis. Even the widely held theory of ketogenesis that it is caused by 
increased fatty acid mobilization has recently been challenged. (35) 
The controversies regarding the regulation of gluconeogenesis 
indicate the serious difficulty that a modeler faces, in trying to 
arrive at a reasonable representation for a given process or subsystem. 
Even the bare minimum information concerning stimulus and response is 
not available in many instances. The picture one obtains from the in-
creasing mass of physiological investigations is neither clear nor 
consistent. The conflicting results clearly indicate the fact that the 
metabolic plant is comprised of several intercoupled loops with several 
hormonal controls and emphasize the need for a consistent investigative 
framework for the overall process. Alti1ough a great amount of physiology 
has yet to be learned about the relevent subsystems involved before a 
definitive model can be established, it is the author's contention that 
the systems analyst can contribute to this effort by systematizing the 
known physiologic facts about the metabolic processes in a consistent 
mathematical framework, by proposing to the physiologist specific 
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experiments suggested by model building, simulation and analysis and by 
determining analytically the consequences of conflicting theories on 
the operation of specific portions of the overall plant. 
It should be noted that the representation shown in Figure 4 
takes into account gluconeogenesis from all the major precursors of this 
process, viz., amino acids, lactic and pyruvic acids and glycerol. In-
creased mobilization of glycerol concomitant with FFA under conditions 
of increased lipolysis can directly account for enhanced gluconeogenesis 
from glycerol when the plasma FFA level is elevated. Under basal condi-
tions, the glucose utilization rate is approximately l50 mg/min~lTIPS F 
The contribution by gluconeogenesis is assumed to be about lOO mg/min. 
The balance is supplied by glycogenolysis. If glycogenolysis produces 
glucose at a constant rate of 50 mg/min it would take more than l6 hours 
to deplete 50 gm. of stored glucose. Since liver glycogen is not dim-
l inished by more than 50 gm. under basal conditions? the values chosen 
for the basal rates of glycogenolysis and gluconeogenesis seem reasonable. 
(ii) In his refined four hormone model Charette lumps glucose 
uptake of muscle and adipose tissue together and represents them in one 
block which he calls the peripheral glucose utilization sink. He 
assumes that the uptake of glucose by peripheral tissues is stimulated 
by interstitial glucose concentration and enchanced by interstitial insulin 
concentration. The peripheral glucose uptake certainly depends.upon 
both glucose and insulin concentrations in the interstitial space. 
i. Refers to equivalent glucose mass. It is asswned that liver 
glycogen stores have a maximum value equivalent to about l25 gm. 
of glucose in a healthy individual and that they do not normally 
fall below 75 gm. 
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However, insulin undoubtedly plays a more decisive role in facilitating 
the transport of glucose from the interstitial space across the cell 
membrane of the peripheral tissues. There may be transport by simple 
diffusion in the absence of insulin at very high concentrations of 
glucose as seen in uncontrolled diabetes. It is assumed that in the 
range of glucose concentration that one normally encounters, the uptake 
of glucose by peripheral tissues is negligible in the absence of insulin. 
Thus in the model proposed here the peripheral glucose utilization is 
independent of interstitial glucose concentration. It is assumed to be 
stimulated by interstitial insulin concentration. Christensen and 
Orskov( 37) have recently reported a highly significant correlation be-
tween muscular glucose uptake and simultaneous arterial serum insulin 
concentration. They found no correlation, on the other hand, between 
glucose uptake and simultaneous arterial glucose concentration. Their 
conclusions are based on ~easurements of glucose uptake in the forearm 
muscles of nondiabetics. 
Charette assumes the peripheral glucose uptake to be inhibited 
by interstitial GH. This inhibitory effect is indirectly present in 
our model. Based on the findings of Rabinowitz etKal~PBFI increased 
levels of interstitial GH are assumed to enhance FFA oxidation by muscle. 
This in turn inhibits muscle uptake of glucose as suggested by Randle 
and his associates~ P9 F Increased levels of GH have no effect on glucose 
uptake by adipose tissue in our model. This seems to be significant 
only at very high concentrations of GH as seen in acromegaly. For in-
stance, Rabinowitz et.al. found a reduction in glucose uptake b~ forearm 
adipose tissue at a local GH concentration of about 400 ng/ml which is 
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well above the levels normally encountered, The exclusion of the GH 
effect on adipose tissue glucose utilization does not affect our results 
appreciably. 
According to Randle et.al. the altered rates of glucose phos-
phorylation, glycolysis and pyruvate oxidation are the consequences of 
an increased rate of fatty acid oxidation, Hence muscle FFA oxidation 
has been assumed to be the variable that inhibits muscle glucose utiliza-
tion. This and the assumption that muscle FFA oxidation is independent 
of plasma FFA concentration (see Page 39) indicate that an increased 
plasma FFA level per se does not cause a decrease in muscular glucose 
uptake. In support of this view, Schonfeld and Kipnis(40) observe that 
in man plasma FFA level should be increased by 300-400% before a detect-
able decrease in peripheral glucose utilization is noted, 
(iii) The third modification that has been made in Charette's 
refined four hormone model is the introduction of an interstitial com-
partment for glucose distribution. Charette assumes for the distribution 
of glucose a single compartment comprising of plasma, interstitial fluid 
and liver and RBc1 intracellular fluid. The volume of the compartment 
is taken to be 17.51. in a normal 70 kg. man - 3.51. of plasma and 
10.51. of inLerstitial fluid with the balance accounting for liver and 
RBC volumes. Suppose 35 gm. of glucose is given intravenously over a 
period of several minutes. Assuming that glucose is not degraded in 
the body during infusion and further that the distribution of glucose is 
instantaneous, the peak glucose concentration attained would be exactly 
1 Abbreviation for red blood cells. 
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200 mg% above the nominal fasting level. It is less in fact due to the 
utilization of glucose during the infusion period and the time constant 
associated with its distribution. On the other hand, the peak deviation in 
plasma glucose level has been observed to be greater than 250 mg% in 
glucose tolerance tests after an IV glucose load of 35 gm. given in a 
period of 3 to P~ minutes (see Figure 14, for example). The differ-
ence is certainly more than the experimental errors one would expect. 
The discrepancy in the peak value of glucose concentration that one 
obtains with a single compartment model for glucose distribution necessi-
tated the introduction of a second fluid compartment. The two com-
partments, one for plasma, liver and RBC and another for interstitial 
fluid, are coupled by means of a constant that accounts for diffusion. 
Since the transfer of glucose across the liver and RBC is extremely 
rapid( 4l) their volumes are lumped with plasma volume. 
Moreover the refined continuous measuring devices that are now 
available for the measurement of glucose concentration( 42 ) justify to 
some degree the somewhat complex two compartment model for the dynamics 
of glucose distribution. Strictly speaking, one ought to have two com-
partment representation for the distribution dynamics of all substrates 
and hormones. But if nothing is to be gained by having two compartments, 
single compartment representation, being·simpler, is the obvious choice. 
Thus the choice for FFA distribution is a single compartment model which 
includes plasma and interstitial fluid. As more refined techniques be-
come available for the measurement of FFA concentration, one may have to 
use a two compartment model for FFA distribution also. For the time being 
a single compartment model suffices for our purposes. 
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Other subsystems in the glucose model are: glycogenolysis, 
glycogenesis1 and renal excretion. All these are stimulated by glucose 
error, the latter two by negative glucose error (glucose concentration 
above nominal) and the former by positive glucose error (glucose con-
centration below nominal). Glycogenolysis in enhanced by glucagon and 
epinephrine and glycogenesis by insulin. Glycogenesis is cut off once 
liver glycogen stores reach their full capacity (equivalent to about 
125 gm. of glucose). Renal excretion is essentially zero below an 
assigned threshold value of plasma glucose concentration. Utilization 
of glucose by the brain and RBC is a constant independent of both 
plasma and interstitial glucose concentrations. 
3.2.2. Models for Hormone Controllers. 
The models for the four hormone controllers are shown in 
Figures 5A and 5B. Except for the glucagon controller the others are 
the same as the ones proposed by Charette~ O F A single compartment model 
has been chosen for glucagon distribution and degradation considering 
its low molecular weight (relative to insulin and GH) and the fact that 
its degradation takes place mainly in the liver which has a rich supply 
of blood. Glucagon response to DI glucagon in a normal subject reported 
by Samols et.al.( 43 ) indicates that a single compartment representation 
of distribution and degradation is quite adequate. 
l Includes other hepatic pathways of glucose also. Thus it re-
presents the liver uptake of glucose when the plasma glucose 
concentration is above nominal (see also Page 83). 
GLUCOSE ERROR 
(mg%) 
GLUCOSE ERROR 
RATE (mg %/min) 
SECRETION 
SECRETION 
IV INSULIN 
(mU/min) 
PLASMA EPINEPHRINE 
CONC. (ng/ml) 
EPINEPHRINE 
INHIBITION 
INSULIN CONTROLLER 
PLASMA 
DEGRADATION 
PLASMA 
DISTRIBUTION 
DIFFUSION 
CONSTANT 
INTERSTITIAL 
DISTRIBUTION 
J 
J 
INTERSTITIAL ~ I 
DEGRADATION 
PLASMA CONC. 
(µ.U/ml) 
INTERSTITIAL CONC. 
(µ.U/ml) 
Figure 5A. Models for Hormone Controllers - Insulin and Epinephrine. 
I 
w 
VI 
I 
GLUCOSE EF 
(mg%) SECRETION 
IV GLUCAGON 
(µ.g/min) 
+ 
GLUCAGON CONTROLLER 
IV GH 
(µ.CJ/min) "- I 
GLUCOSE ERROR 
(mg%) SECRETION 
+ 
DISTRIBUTION 
DEGRADATION 
I PLASMA I 
: DEGRADATION . 
PLASMA 
DISTRIBUTION 
DIFFUSION 1 ... CONSTANT 
INTERSTITIAL 
DISTRIBUTION · 
INTERSTITIAL 
DEGRADATION 
GROWTH HORMONE CONTROLLER 
J 
J 
+ 
(I 
J 
Figure 5B. Models for Hormone Controllers - Glucagon and GH. 
PLASMA CONC. 
(ng/ml) 
I 
w 
PLASMA CONC. 0\ I 
(ng /ml) 
INTERSTITIAL CONC. 
(ng/ml) 
-37-
Simulation studies pointed out the need for some minor changes 
in Charette's insulin controller. Insulin secretion proportional to 
glucose error has a lower saturation value of zero in Charette's version. 
This was made positive in all the simulation studies reported here. 
Also a small amount of insulin secretion was assumed in the presence 
of epinephrine. In other words epinephrine does not turn off insulin 
secretion completely. 
3.2.3. The FFA Model. 
The major factors involved in fatty acid metabolism are shown 
in Figure 6. The intracellular FFA concentration is shown to be con-
tained in a single intracellular pool, although this is actually not 
l the case. The flow of FFA into and out of this pool is controlled by 
various hormonal and other factors. In our model the representations 
of the processes that control the movement of FFA into and out of extra-
cellular fluid are assumed to include the mechanism of transport across 
the cell membrane. Thus, for example, the endogenous release rate of 
FFA due to epinephrine is directly related to the plasma concentration 
of epinephrine. The effects of transport are thus lumped. The role of 
adipose tissue intracellular FFA in the control of storage and release 
of fatty acids is not clear at the present time. 
l In fact it has been shown that there is nf44' single intracellular FFA pool for lipolysis and esterification. It is well known 
that the vast majority (over 9CJ'/o) of lipid in adipose tissue is 
stored in the form of 'IU which is seen morphologically as one or 
more very large spherical droplets. Much less is known concern~4 the precise distribution and state of FFA within the adipose cell. 5) 
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The proposed FFA model is shown in Figure 7. A single com-
:i;artment representation has been chosen for FFA distribution in the 
extracellular space. The time constant was taken to be around 2 min-
utes in all simulations. The corresponding half-life is 1.4 minutes. 
The figure is reasonable considering the extremely short life of FFA 
in plasma~ 4S F The major assumptions made in the construction of the 
model are the following: 
(i) The effects of glucose on adipose tissue are mediated 
entirely through insulin. 
(ii) Epinephrine and GH are the most predominant lipolytic 
hormones which participate in the short-term responses reported here. 
(iii) Muscle uptake of FFA for immediate oxidation is independent 
of plasma FFA concentration. 
(iv) Plasma FFA concentration is the stimulus for FFA uptake by 
liver and muscle for storage and FFA uptake by liver for production 
and release of TG and ketones. Furthermore the rate of utilization of 
FFA along these pathways ~s saturation-limited at both ends. 
FFA utilization: The major pathways of FFA utilization are: 
(i) 
(ii) 
(iii) 
(iv) 
Muscle oxidation. 
Muscle and liver storage. 
Liver TG production. 
Liver ketone production. 
(i) Muscle oxidation: It is known that FFA entering the muscles 
are partly oxidized and partly stored. The fraction of FFA turnover 
that is immediately oxidized seems to be rather constant and independent 
of plasma FFA level. 
Issekutz et.al. (47) 
Evidence to this fact has been obtained by 
Their conclusions are based on experiments with 
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humans. In further evidence of our representation of muscle FFA 
oxidation Fredrickson et.al. ( 5 ) observe that in man it was not found 
possible to prevent appreciable oxidation of plasma FFA by supplying 
an excess of calories as carbohydrate. This would not be true if 
muscle oxidation of FFA depended upon plasma FFA level, for the latter 
is decreased by supply of carbohydrates. Muscle, in this context, 
refers to all the major utilizers of FFA such as skeletal muscle, heart 
muscle, bronchial musculature, etc. Adipose tissue and liver are ex-
eluded. FFA oxidation by the liver is included in the liver ketone 
production block. Adipose tissue needs of FFA are presumably met from 
its own stores of 'IG. Fredrickson et.al. point out that the movement of 
endogenous FFA from plasma back to adipose tissue is considerably less 
than the forward reaction. Bragdon and Gordon( 4S) found only 1-2% of 
injected labeled FFA in adipose tissue of both fasted and carbohydrate-
fed rats. Hence it is assumed that there is no appreciable flow of 
FFA from plasma into adipose tissue. Muscle oxidation of FFA is 
enhanced by both GH and epinephrine in our model. Increase of muscle 
FFA uptake in the presence of GH has been reported by Rabinowitz etKa1~ PU F 
The increase due to epinephrine includes the changes due to its effects 
upon flow as well as its direct effect on cardiac and vascular FFA 
oxidation. It should be noted that the two effects of GH and epinephrine 
on FFA metabolism, namely FFA mobilization and increased muscle FFA 
oxidation are independent in our model. 
(ii) Muscle and liver storage: This block represents the fraction 
of FFA turnover that is stored in muscle and liver in esterified form. 
In liver, newly synthesized 'IG are apparently contained in at least two 
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functional compartments, one slow and another that turns over rapidly~ S F 
Liver storage included here is associated with the slow turning portion 
of the newly formed TG. 
(iii) Liver TG production: This subsystem is identified with the 
portion of the newly synthesized hepatic TG that turns over rapidly. 
(iv) Liver ketone production: This subsystem includes liver 
oxidation of FFA and the resulting ketogenesis~ The mathematical 
function chosen for this process has a lower saturation level that 
represents the minimum FFA requirements of the liver. Liver is known 
to utilize mainly FFA for oxidation. 
It should be noted that the processes (ii), (iii) and (iv) 
listed above depend on plasma '-FFA concentration. The mathematical 
functions chosen for representing these processes are identical except 
for the saturation levels. Although it is possible to lump (ii), (iii) 
and (iv) into a single process (which might be called the FFA utilization 
sink) without altering any of the simulation results which we shall 
discuss later, this was intentionally not done, thus leaving scope for 
building the model further. With the subsystems shown in Figure 7 for 
FFA utilization it is easier to couple the TG and ketone loops. There 
is, of course, no unique way of choosing the subsystems. The choice is 
dictated by simplicity, ease with which the relevant subsystems can be 
identified and the facility it provides for building the model further 
l The theory that ketogenesis is directly related to mobilization 
of FFA from the periphery andEth~ir subsequent oxidation in liver 
has recently been challenged. 35) 
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without making drastic changes in its basic structure. 
Lipolysis: The FFA model includes the effects of three 
hormones which are known to affect lipolysis profoundly ~ insulin, 
epinephrine and GH. The effects of other lipolytic hormones can easily 
be incorporaten, if desired. They are not included since they do not 
play any significant role in the short-term responses that we are mainly 
concerned with. 
(i) Insulin: The inhibitory effect of insulin on lipolysis is 
well-known. The concentration of interstitial insulin and its rate are 
both assumed to stimulate this inhibition. The rate dependence was 
found necessary in order to explain the rapid fall of plasma FFA con-
centration following DI administration of glucose or insulin. The time 
constants of the two lag elements associated with insulin action were 
chosen to be the same in all simulation studies. It is therefore possible 
to simplify the configuration shown in Figure 7 with two time lags to 
one with only one lag element as indicated in Figure 8. Referring to 
Figure 8A 
dzl2 
T30 Cit+ 2 12 = uli 
dz1~ I . 
T31 Clt + zl2 = uli where 
If T30 = T3l' then 
I dzl2 
zl2 = Cit We can represent the dynamics of 
insulin effect on adipose tissue as indicated in Figure 8B. 
It should be noted that the effect of glucose on adipose 
tissue is mediated entirely through insulin in our model. Current 
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theories support this viewpoint. Rabinowitz et.al( 49, 5o) have produced 
evidence to ccnclude that the glucose uptake by adipose tissue (which 
provides a-glycerophosphate, the necessary precursor for the esteri-
fication of fatty acids) alone cannot account for the rapid fall of 
plasma FFA level caused by rv glucose or insulin. 
(ii) Epinephrine: The in vivo effects of epinephrine on humans 
have been studied by Porte et.al.( 5l) The dynamics of FFA release 
shown in Figure 7 is intended to explain the observations of Porte et.al., 
viz., an initial rise in plasma FFA concentration followed by a decline 
to the normal level. An increase in glucose concentration results due 
to enhanced gluconeogenesis and glycogenolysis by epinephrine. The 
initial increase of FFA production is later inhibited once the inter~ 
stitial glucose concentration reaches a certain value, possibly·due to 
re-esterification. There are evidences in the literature in support of 
this idea. Firstly increase of interstitial glucose concentration in-
creases the entry of glucose into adipose tissue and this has the effect 
of improving the supply of a-glycerophosphate necessary for esterification 
of fatty acids. As we mentioned earlier (see Page 31), such an increase 
in the uptake of glucose by adipose tissue may not be significant in the 
absence of insulin whose secretion is blocked by epinephrine( 5l). 
However, it may be sufficient to improve the re-esterification of fatty 
acids and mask the lipolytic action of epinephrine. Secondly, the in-
creased glucose entry could be a direct effect of epinephrine acting on 
the cell membrane. Based on in vitro results using labeled glucose, 
Bray and Goodman( 5z) have reported increased entry of glucose into 
adipose tissue and also augmented incorporation of radioactivity from 
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glucose into glyceride-glycerol by epinephrine. Increased re-esterifica-
tion in adipose tissue could also result from a rise in the level of 
phosphorylase activity caused by epinephrine~ 1S F 
The action of epinephrine on adipose tissue has not been clearly 
elucidated. Brooker and Calvert( 53 ) have obtained dose-response curves 
that have a bell shape for catecholamine-induced lipolysis using 
isolated rat adipose tissue. This suggests the possibility of repre-
senting the lipolytic action of epinephrine in our model by means of a 
bell-shaped nonlinear curve relating plasma epinephrine concentration and 
FFA release rate. However, this would imply continued lipolysis for 
certain low levels of epinephrine in spite of increased muscle FFA 
oxidation and thus cannot be used to explain the in vivo observations on 
humans. Several suggestions have been made in the literature to explain 
the effects of epinephrine on adipose tissue. Bally et.al. (54 ) have 
suggested that as a working hypothesis the adipose tissue intracellular 
concentration of FFA may be assumed to inhibit the release of FFA from 
adipose tissue stores. Rodbell( 55 ) also has advanced this viewpoint. 
Based on the above hypothesis the lipolytic action epinephrine was first 
modeled as shown in Figure 9. Although this representation successfully 
reproduced the FFA response to a dose of rv epinephrine, it gave rise 
in the case of rv insulin to an early impairment of FFA mobilization 
offsetting the rebound increase of plasma FFA concentration, It was 
found difficult to reproduce the FFA response caused by insulin hypo-
glycemia. Therefore the representation shown in Figure 7 was chosen. 
It serves as a working hypothesis to explain the FFA re-
sponses to both IV insulin and rv epinephrine without introducing 
ACCUMULATION 8 
-
DEGRADATION 
a 
·-
PLASMA EPINEPHRINE 
LIPOLYSIS 
FFA RATE 
-
CONG. ( ng/ml} (µ.Eq/min) 
Figure 9. An Alternative Representation for Dyna.mies 
of FFA Release by Epinephrine. Accumulation and de-
gradation is represented by a first-order lag and 
lipolysis by a saturation-type nonlinearity. The 
saturation level is a linear fwiction of the variable a. 
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additional complications. In a small measure this demonstrates how 
models can be used to test alternate hypotheses. 
(iii) Growth Hormone: GH has the following effects on FFA metabol-
ism. First there is an initial decrease of plasma FFA level. This is 
accounted by the increased FFA oxidation by muscle as suggested by 
Rabinowitz et.al. (38) Secondly there is a delayed but significant 
lipolytic effect. A lag eiement accounts for the delay in the lipolytic 
action of GH in our model. 
Under basal conditions, FFA turnover rate lies in the range 
400 - 900 µEq/min ~ 7) It was taken to be around 700 µEq/min in all 
simulation results reported here. The contribution of circulating 
epinephrine and GH to fasting lipolysis was assumed to be only a very 
small fraction of the turnover. In other words, increased rates of 
lipolysis were assumed to be mostly due to low levels of insulin1 under 
fasting conditions in accordance with the suggestion by Cahill etKal~RS F 
Numerical values for the basal rates of the various utilization pathways 
were obtained from the review article by critz~lTF 
3.3. The Basic Building Blocks. 
The basic building blocks used in the construction of the 
model are shown in Figure 10. In addition, the model uses multipliers, 
gain constants and summers. If the nonlinearity depends on more than 
one parameter, its saturation level is linearly dependent on each of 
l With glucose infusion studies on humans, Goodner et.al.(57) ob-
tained results which "point to the operation of a glucose sensitive 
center which regulates lipolysis in the fasting individual inde-
pendent from insulin secretion and probably mediated by the 
sympathetic nervous system." 
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the parameters. It should be noted that the switch shown in Figure 10 
does not have a sharp cut-off. A hyperbolic tangent function with a 
very high slope at the mid-point was used in all computer programs to 
represent the switch • 
Many metabolic processes such as glycogenesis, glycogenolysis, 
lipolysis, etc. represent the overall effect of a series of enzyme-
catalized reactions. The choice of saturation-type nonlinearity (with 
or without parameter dependence) for characterizing lumped processes 
arises from the fact a multi-enzyme sequence of reactions is rate-limited 
at some saturation value. For a further discussion on this the reader 
is referred to Section 3.4 of Charette's thesis~ O F Referring to Figures 
4,5, and 7, a nonlineari~yI either parameter dependent or parameter 
independent as the case may be, characterizes each of the following 
elements of the system: gluconeogenesis, glycogenolysis, glycogenesis, 
muscle utilization and adipose tissue utilization of the glucose model; 
the secretion elements of the contro~ler models; lipolysis, muscle and 
liver storage, liver TG production and liver ketone production of the 
FFA model. Renal excretion of glucose is zero below a certain value of 
plasma glucose concentration and increases linearly above this value. 
Brain and RBC utilization of glucose is a constant. Muscle oxidation 
of FFA is represented by linear functions of both plasma epinephrine 
concentration and interstitial GH concentration. Epinephrine inhibition 
of insulin secretion is a switch. All the lag elements and distributions 
in the glucose and FFA models are first-order lags. Hormone distribution 
is a constant - reciprocal of the distribution volume. 
The following examples illustrate the construction of the 
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model. 
Let 
Then 
where 
Let 
Example 1: Gluconeogenesis 
Stimulus - Plasma FFA concentration, f (µEg/L). p 
Response - Gluconeogenesis rate, x1 (mg/min). 
Parameters - Plasma concentrations of glucagon and 
epinephrine, and u3p respectively (ng/ml). 
Fasting values of and respectively 
x1~ = Lower saturation value of gluconeogenesis rate 
x1h = Higher saturation value of gluconeogenesis rate 
when and 
tanh[~ 1 (f - f )} x p p 
f are constants. p 
Example 2; Insulin distribution and degradcction in plasma and 
interstitial fluid 
w1 = Net endogenous insulin secretion (mu/min) 
= IV insulin input (mu/min) 
Then 
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KlO = Plasma insulin degradation constant (L/min) 
Kll = Diffusion constant (L/min) 
~O = Interstitial insulin degradation constant (L/min) 
= Plasma insulin concentration (µU/ml) 
l\i = Interstitial insulin concentration (µU/mfJ) 
V = Plasma vo1ume (L) p 
Vi =Interstitial fluid volume (L) 
Example 3: Dynamics of FFA release by epinephrine 
Stimulus - Plasma epinephrine concentration, u3 (ng/ml). p . 
Response - FFA release rate, y2 (µEq/min). 
Parameters - Interstitial glucose concentration, gi (mg'fo) 
and modified value of u3p (ng/ml). 
u is equal to 3P u3p above a certain value of gi denoted 
it is zero for low values of That is, 
if g. >>g. 
l. l. 
U, 0 j};I if g. << g. l. l. 
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It is represented as follows: 
u' 3P 
is chosen so as to obtain the.desired switching charac-
teristic. Under fasting conditions, gi << gi and he'nce uP~ = O. 
I.et 
Then 
where 
u3P = Fasting value of u3P 
Y
2
h = Higher saturation value of epinephrine-induced 
lipolysis rate when ~; = o. The lower saturation 
value is zero. 
Y2h = y2h + 
Y2h 
Y2 = 2+ 
and are constants. 
3.4. The Results. 
The validity of the proposed model was tested with data 
obtained both from the Physio-Chemical Automation Research Laboratory 
at Cedars-Sinai Medical Center, Los Angeles, california and from the 
Research Laboratories of the Diabetes Foundation, Joslin Clinic, Boston, 
Massachusetts. The data were from a single test subject in each case. 
Since the parameters of the model characterize the peculiarities of the 
metabolism of a given individual, it does not make sense to use the 
average data from several test subjects. Numerical values for the 
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parameters were obtained initially in most instances from physiologic 
and medical literature. They were then refined to fit the experimental 
data on glucose, insulin and FFA taken after IV administration of either 
glucose or insulin. No sophisticated curve-fitting techniques were 
employed. The fit was based on judgement by the eye. In all cases the 
experiment was conducted after an overnight fast. In a few instances 
the parameter values could be obtained directly from the experimental 
data. For example, in one of the simulation studies insulin response 
to IV insulin was used to obtain the parameter values associated with 
insulin degradation. A time delay between 20 to 60 seconds in the 
input was assumed in all simulation studies to account for the delay 
in injection due to tubing, etc. It was necessary in order to obtain 
peak-times close to the observed values. All simulation studies were 
done on an IBM 7094 computer. 
Figure 11 shows the simulated and experimental data from a 
male test subject after 30 gm. of IV glucose. Glucose concentration 
was measured continuously in this case using a continuous glucose 
monitoring device< 42 >. An on-line PDP-8/s computer along with an 
A/D convertor was used to print out the values of glucose concentration 
at some desired instants of time~ RU F These values have been reproduced 
in Figure ll. Glucose was injected at a constant rate of 10 gm/min with 
the aid of a pump. The sampling times for the batch samples for the 
measurement of insulin and FFA concentrations were accurate to the 
second and special techniques were worked out to ensure this. Time 
was measured from the beginning of infusion. Significant changes in 
the metabolic variables occur in many instances immediately following 
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the disturbance introduced into the systerr. - a very rapid rise in 
plasma glucose concentration after DI glucose infusion, for example. 
It is therefore absolutely important to make measurements from the 
beginning of infusion. 
Figure 12 shows the results on the same subject after lU of 
insulin injected intravenously at a constant rate over a period of 3 
minutes. The last two experimental values of FFA concentration do not 
fit very well with the simulated curve. This could be due to other 
lipolytic hormones, not included in the model, operating under hypo-
glycemic conditions. Figure 13 shows a prediction result. Without 
altering the parameter values obtained in the two previous simulations, 
the ability of the model to reproduce the glucose response of the 
same subject to 15 gm. of DI glucose input was tested. The experiment 
was done twice separated by 8 weeks. The results were practically 
identical. The average of the two sets of experimental data is shown 
in Figure 13. The model has reproduced fairly well the peak and the 
time-to-peak, although the difference is somewhat large in the tail 
portion of the response. The results are good considering the prelimi-
nary stage of the modeling efforts reported here. 
The errors in the measurements of glucose and FFA concen-
trations were less than ?.% and 4% respectively. The expected error in 
the measurement of insulin concentration was about 5oa/o at lOµU/ml and 
about 5% at OMM~1r/mlK The experimental set-up was same for all experi-
ments. Hence the delay in injection was assumed to be the same in all 
simulations. The experiments were done after :.:1 overnight fast, thus 
making sure that the pretest regimen of the subject was same for all 
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of them. At this stage of modeling it is absolutely important that 
we disturb the system from the same initial state in all studies. As 
we understand more about the system we may be able to remove this 
restriction. 
Figures 14 and 15 show the simulated and experimental data 
from normal subjects after 35 gm. of IV glucose. Experimental data 
were obtained from the research laboratories in Boston (J. S. Soeldner, 
Personal Communication). All quantities were measured at the sampled 
intervals shown. Glucose concentration was measured with a Technicon 
autoanalyzer. The standard deviations in the measurements of glucose, 
insulin and FFA concentrations were about 2%, &fa and 15%, respectively. 
Figures 16 through 20 show the simulation results of IV 
injections of glucagon, epinephrine, GH and insulin on subject 174 
(see also Figure 15). Although we do not have experimental data for 
comparison, these results indicate that the proposed model has 
enough flexibility to reproduce clinical observations after IV injections 
of the hormones listed above. The model failed to reproduce the report-
ed responses( 59) to continuous (for more than one hour) IV glucagon 
infusion. Prolonged infusion of glucagon lowers the plasma FFA con-
centration which stays low till the infusion is withdrawn. Since the 
effects of FFA are mediated through only insulin in our model, the 
simulation studies indicated an increase of plasma FFA level after 
insulin reached its normal level. Our model does not include the 
effect of glucagon on insulin secretion. If it did the plasma FFA level 
would stay low. 
The model yields an almost linear increase in glucose con-
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Figure ll. Responses to 30 gm. of IV glucose injected 
at a constant rate over a period of 3 min. Subject: B. 
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Figure 14. Responses to 35 gm. of IV glucose injected 
at a constant rate over a period of 3 .5 min. Subject:" 186. 
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centration to IV epinephrine infusion as shown in Figures 17 and 18, 
although the increase is not quite linear according to the results 
reported by Porte et.al.(5l) Some refinements of the functions associat-
ed with the responses to IV epinephrine (dependence of gluconeogenesis 
and glycogenolysis on plasma epinephrine concentration, for example) 
may be necessary. It is premature to make such refinements at this 
stage of modeling. To the author's knowledge the results of Porte et.al. 
are the only ones reported in the literature concerning glucose, insulin 
and FFA responses to IV epinephrine. More clinical tests which would 
reveal the details and the salient features of these responses are 
needed before one attempts any refinements of the mathematical functions 
or changes in the model. The above comment applies equally well in the 
case of IV GH infusion also. The simulation results of IV injections 
of insulin (l.5U and 3U) depicted in Figure 20 compare favorably 
well with the observations of Greenwood etKa1~ SMF 
In a complex model such as the one proposed here, the modeler 
has a wide choice of parameters to fit the experimental data. However, 
a serious restriction is that all the parameter values should lie 
within physiologic range and all the physiologic variables should vary 
within an expected range for the particular experiment in question. 
Care was taken to ensure this in all the simulations. The changes, 
as obtained from simulations, in plasma concentrations of epinephrine, 
glucagon and GH of subject 174 during IV glucose and insulin tolerance 
tests are shown in Table 3. Not only are all the quantities within 
physiologic range but also they agree with the observations reported 
in the literature. For example, the maximum value of plasma epinephrine 
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35 gm. IV Glucose 3U IV Insulin 
Time 
(min. ) Epinephrine Glucagon GH Epinephrine Glucagon GH 
-
0 0.10 o.4o 2.00 0.10 o.4o 2.00 
3 0.02 0.29 1.83 0.10 o.4o 2.01 
6 0.19 0.19 1.63 o.42 0.80 4.34 
10 0.02 0.11 1.42 0.99 2.42 16.32 
15 0.00 0.05 1.22 1.06 3.63 28.22 
20 o.oo 0.03 1.06 1.01 4.13 36.99 
30 o.oo 0.01 0.82 0.87 4.08 47.47 
40 0.00 0.01 o.66 0.58 3.27 48.34 
50 0.04 0.09 0.61 0.23 1. 72 35.95 
60 0.13 0.36 1.17 0.16 0.94 26.44 
70 0.20 o.68 2.62 0.12 0.63 20.45 
80 0.20 0.80 3.78 0.11 o.48 16.35 
100 0.18 0.77 4.56 0.09 0.37 11.09 
120 0.17 0.72 4.76 0.08 0.33 7.86 
TABLE 3 
Plasma concentrations of epinephrine, glucagon and GH during 
IV glucose and::insulin tolerance tests (subject 174) as 
obtained from simulations. All concentrations are in ng/ml. 
Time is given from the beginning of infusion. 
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concentra tion is 1.06 ng/ml after 3U of IV insulin; Vendsalu( 6l) reports 
a maximum value of 0.8 ng/ml under hypoglycemic conditions. IV glucose 
reduces plasma GH level to very near zero as reported by Boden etKa1~ SO F 
With the parameter values chosen, maximum pancreatic secretion 
of insulin would yield a plasma insulin concentration of about 250 µU/ml 
which is in the vicinity of the upper physiologic limit~PTF The maximum 
hormone-independent glycogenesis rate is 250 mg/min. Under the influence 
of insulin it increases to 850 mg/min when the plasma insulin level is 
about 250 µU/ml. Thus insulin increases the rate of hepatic uptake of 
glucose by a factor of about three which has been reported~ SP F Maximum 
uptake of glucose by muscle and adipose tissue occurs at an interstitial 
insulin concentration of about 70 µU/ml corresponding to a plasma con-
centration of 140 µU/ml.under steady conditions. Christensen and Orskov(37) 
report maximum glucose uptake by the forearm muscles at a plasma insulin 
level around 200 µU/ml. Several such agreements support the physiologi-
cal basis of the proposed model (see Section 3.5 for typical parameter 
values and Figures 16 through 20 for ti values associated with 
2 
hormone distribution and degradation). Furthermore the simulation 
studies on subject 174 yielded a net glucose uptake of 15 gm. by muscle 
in 60 minutes after an IV glucose load of 35 gm. Butterfield et.al.(64) 
estimate a value of about 16 gm. after 25 gm. of IV glucose. Similar 
values were obtained in other simulation studies also. The renal 
glucose excretion of subject B was measured after IV glucose tolerance 
test (Figure 11) and found to be 0.5 gm.; the simulation gave a value 
o.6 gm. 
3,5 A TyJ?ical Example of the Proposed Model. 
The equations used in the simulation studies of subject 174 are 
presented in this section as an example of the proposed model. The 
numerical values indicated are typical ones for the parameters. The 
parameter values for simulation of responses of subjects B and 186 were 
chosen in the same vicinity. The graphs shown in Figures 15 through 20 
were generated using these equations and parameter values. 
Glucose model: 
t = 
gp = 
gi = 
r = 
e = 
v = p 
V. = 1 
v = e 
Vt = 
Tl = 
T2 = 
K = g 
I = g 
xl = 
x2 = 
Time (min) 
Deviation of plasma glucose concentration from nominal (mg%) 
Interstitial glucose concentration (mg%) 
Nominal or reference level of plasma glucose (mg%); taken to 
be 0 
Error in plasma glucose concentration (mg%) 
Plasma volume (L) 
Interstitial fluid volume (L) 
Extracellular fluid volume (L) 
Volume of plasma, liver and RBC (L) 
Time constant associated with plasma glucose distribution(min) 
Time constant associated with interstitial glucose distribu-
tion (min) 
Diffusion constant (100 ml/min) 
IV glucose input (mg/min) 
Gluconeogenesis (mg/min) 
Glycogenolysis (mg/min) 
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x 3 = Net glucose input into plasma (mg/min) 
= Glucose error presented to the liver (mg%) 
= Glycogenesis (mg/min) 
x6 = Renal excretion (mg/min) 
= Brain and RBC utilization (mg/min) 
x8 = Muscle utilization (mg/min) 
= Adipose tissue utilization (mg/min) 
x10 = Net plasma glucose utilization (mg/min) 
= Error in plasma glucose rate (mg/min) 
e2 = Error in interstitial glucose rate (mg/min) 
zl = gp ; z3 = gi 
z5 = Amount of glycogen in the liver (gm) 
r = 0 
e = r - g = - g p p 
xlh = 175 + 300 (u2p- 0.1) + 500 (u3p- o.4) 
= 
x1h + 25 x1h - 25 
--- + tanh {0.003(f - 870)} 
2 2 p 
x2h = 200 + 250 (u2p- 0.1) + 400 (u3p- o.4) 
= 
g g 
x4 = ~ - ~ tanh {0.6(z5- 125)} 
x 5h = 250 + 2.5(u1p- 9) 
x = 7 
x = 9 
xlO = 
el = 
e2 = 
dz1 
= dt 
dz2 
= dt 
dz3 
= dt 
dz4 
= dt 
dz 5 
= dt 
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x x 
5h + 5h tanh {0.025(x4- 160)} 2 2 
1 + tanh{0.4(g - 130)} 
2.2 g 
p 2 
98.57 
1160 - 4(y5- 100) 
1160 1160 
- 2- + - 2- tanh {0.082(uli- 34.5)} 
x5 + x6 + x7 + Kg(gp- gi) 
x3 - xlO 
Kg(gp- gi) - (x8+ x9) 
z2 
el 
z2)/Tl <1ov -
t 
Z4 
e2 
<1ov. - z4)/T2 
J. 
(x5- x2 )/1000 
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Fasting level of plasma glucose = 57.0 mg% 
Glucose turnover under fasting conditions = x3 ( 0) = x10 ( 0) = 144. 887 mg/min 
Insulin Controller Model: 
uli 
w 10 
w 
11 
w 
lh 
w 
1 
w 
10 
w 
11 
w 
lh 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
Plasma insulin concentration (µU/ml) 
Interstitial insulin concentration (µU/ml) 
Insulin secretion, concentration dependent (mU/min) 
Insulin secretion, rate dependent (mU/min) 
Insulin secretion without epinephrine inhibition (mU/min) 
Net insulin secretion (mU/min) 
IV insulin input (mU/min) 
Plasma insulin degradation constant (L/min) 
Diffusion constant (L/min) 
Interstitial insulin degradation constant (L/min) 
58 +
2
3.9 + 58 - 3 .9 tanh {0.02(g - 120)} 
2 p 
w + w 
10 11 
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w 
1 = 
wlh - 3 
2 tanh {20(u3p- o.4)} 
dz 6 
dt 
dz7 
dt 
= 
= 
v = 3.5; p 
KlO = 0.3; Kll = o.4; Kl2 = o.4 
Glucagon Controller Model: 
v. = l0.5 
l. 
u2p = Plasma glucagon concentration (ng/ml) 
w 
2 = Glucagon secretion (µg/min) 
r 2 = IV glucagon input (µg/min) 
K2 = Degradation constant (L/min) 
w = 9 · 98 - 9' 98 tanh { O. 061 ( g + 20)} 2 2 2 p 
v = v + v. = i4.o 
e p l. 
-75-
Epinephrine Controller Model: 
u3p = Plasma epinephrine concentration (ng/ml) 
~PM = Epinephrine secretion, concentration dependent (µg/min) 
w31 = Epinephrine secretion, rate dependent (µg/min) 
w 
30 
w 
31 
w 
3 
dz9 
dt 
= 
= 
= 
= 
= 
= 
= 
= 
= 
Net epinephrine secretion (µg/min) 
IV epinephrine input (µg/min) 
Degradation constant (L/min) 
4.o - 4.o tanh 
2 2 {0.3(z2+ 15)} 
w + w31 30 
(w + 3 I3 - K3z9)/Ve 
0.1 
Growth Hormone Controller Model: 
u4p = Plasma GH concentration (ng/ml) 
u4i = Interstitial GH concentration (ng/ml) 
W4 = GH secretion (µg/min) 
I 4 = IV GH input (µ g/min) 
K40 = Plasma GH degradation constant (L/min) 
K41 = 
K42 = 
zlO = 
W4 = 
dzlO 
= dt 
dzll 
= dt 
zlO(o) = 
K40 = 
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Diffusion constant (L/min) 
Interstitial GH degradation constant (L/min) 
13.26 
2 
13.26 
2 tanh {0.095(gp+ 20)} 
{w4 + I4 - K40zl0 - K4l(zl0- zll)}/Vp 
{K4l(zlO- zll) - K42zll}/Vi 
2.0; zll(O) = 0.9 
0.035; K41 = 0.245 
Free Fatty Acid Model: 
f p 
Y1 
u' 3p 
Y2 
= 
= 
= 
= 
= 
= 
= 
= 
= 
Plasma FFA concentration (µEq/L) 
Time constant associated with insulin effect on adipose 
tissue (min) 
Time constant associated with lipolysis by GH (min) 
Time constant associated with FFA distribution (min) 
Insulin effect on adipose tissue, concentration dependent 
(µEq/min) 
Insulin effect on adipose tissue, rate dependent (µEq/min) 
Net effect of insulin on adipose tissue (µEq/min) 
Plasma epinephrine level as modified by interstitial glucose 
(ng/ml) · 
Lipolysis by epinephrine (µEq/min) 
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Lipolysis by GH (µEq/min) 
Net FFA release (µEq/min) 
Muscle oxidation of FFA (µEq/min) 
Muscle and liver storage of fatty acids (µEq/min) 
FFA utilization for liver TG production (µEq/min) 
FFA utilization for liver oxidation and ketone 
production (µEq/min) 
Y4 = Net FFA utilization (µEq/min) 
e3 = Error in FFA rate (µEq/min) 
dzl2 
= dt 
Y10 = 
Y11 = 
Y1 = 
u' = 3p 
y2h = 
Y2 = 
dzl3 
--= dt 
f p 
dzl2 
z12 = dt 
(uli- zl2)/T3 
680 + 425 680 - 425 tanh {0.745(z12-2 2 
530 + 530 tanh 
2 2 {1o(z12- o.457)} 
Y10 - Y11 
1 + tanh{0.2(g.- 150)} 
1 
u3p 2 
590 
- 450 u3p 
y2h y2h {6(u3P- o.4)} --+ -tanh 2 2 
(u4i- zl3)/T4 
8.5)} 
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Y3 = 5aa + 5aa tanh {a.445(z13- 6)} 2 2 
Y4 = Y1 + Y2 + Y3 
Y5 = laa + 25a(u2p- a.1) + 6(u4i- a.9) 
y6 = 56a ; 22a + 56a ; 22a tanh {a.aa5(fp- 87a)} 
laa + 4a + lOa - 4a t h {a.aa5(f - 87a)} Y7 = 2 an 2 p . 
18a + laa lBa - laa tanh {a.aa5(f - 87a)} Ya = 2 + 2 p 
= 
e3 = Y4 - Y4 
dzl4 
= zl5 dt 
dzl5 e3 
= (y- - zl5)/T5 dt e 
zl2(0) = 4.5; z13 (o) = a.9; z14 (o) = 87a.a; zl5(0) = a.a 
T3 = 3a.a; T4 = 6a.a; T5 = 2.0 
Fasting level of plasma FFA = 87a µEq/L 
FFA turnover under fasting conditions = y4(o) = y4(0) = 7oa µEq/min 
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3.6 The Choice of Parameter Values. 
The numerical values of the parameters for the simulations 
reported in the previous sections were obtained from physiologic and 
medical literature to begin with. They were subsequently refined to 
fit actual experimental data. The physiological considerations which 
led to the choice of the typical parameter values indicated in the last 
section are discussed in this section. Owing to the paucity of experi-
mental data it was not always possible to choose every parameter value 
based on physiological considerations. For example, the author does 
not know of any way of arriving at a number for the constant associated 
with glucose diffusion from the vascular compartment into the inter-
stitial space. The choice was entirely arbitrary for this particular 
parameter. 
Glucose Model: 
(i) Distribution in extracellular space: The parameters are 
and K • g Vt is the volume of plasma, liver, 
RBC and intestinal mucosa and is taken to be 7.0L. Vi is the inter-
stitial fluid volume and is assumed to be l0.5L. T1 is the time con-
stant associated with gluocse distribution in the first compartment 
whose major component is plasma. It is less than one minute and is 
primarily accounted for by the time required for a few complete circuits 
of systemic circulation. T2 is the time constant associated with 
glucose distribution in the interstitial space. It is· also a fraction 
of a minute considering the rapid distribution of glucose in the 
extracellular space. The parameter K was fixed by trial and error g 
in all simulations so a~ to obtain the proper peak and time-to-peak of 
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plasma glucose concentration. 
(ii) Gluconeogenesis: The rate of gluconeogenesis, x1, is 
. byl given 
+ 
where 
As noted on page 30, the basal gluconeogenesis rate is ta>-,n 
to be 100 mg/min. Owen et.a1( 65166 ) have calculated a value of 
33 gm/day for the theoretical maximum glucose turnover after 5 to 6 
weeks of fasting. Since glucose production is entirely due to glu-
coneogenesis after such a prolonged fasting, this directly gives a 
value for the lower saturation level, xlt. x1t = 33 gm/day= 23 mg/min. 
The value for subject 174 is 25 mg/min. 
As the fasting proceeds the plasma FFA level steadily in-
creases; gluconeogenesis is increased and glycogenolysis is depressed. 
Assuming that a double saturation curve (saturation-limited at both 
ends) is a valid representation of gluconeogenesis rate as a function 
,.., 
of fp' fp may lie anywhere within the permissible physiologic range 
1 The definitions of symbols are same as in section 3 .5. The suffixes 
h and t refer to higher and lower saturation values respectively. 
The symbols ~ and ~ are constants associated with the tangent 
hyperbolic function. a and b are constants associated with the 
saturation level function. Capital letters signify fasting steady 
state values? unless they are constants. For example, X is the 
fasting value of xlh when u = U and u = U · -Mfereas 
K 2P 2D 3D 3p' 
, T1, T2 etc. are constants. Small letters a.enote either constants o~ functions of time. 
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of f depending on the number of hours of fast preceding the experi-p 
ment. By insisting that the pretest regimen should be the same for all 
experiments we can make sure that the initial conditions are the same in 
,..., 
all cases. However this does not help us determine the value of f • p 
The difficulty arises from the fact that our FFA-glucose model is only 
a part of a bigger and more complex system with several "outer loops" 
that have been ignored. Since the present model is intended to explain 
only certain short-term effects typically due to disturbances introduced 
after a normal overnight fast, we will assume f = F , the fasting p p 
plasma FFA concentration, with the added requirement that all experi-
ments be performed under identical conditions. It is worth mentioning 
that it is necessary to maintain the subject under controlled dietary 
conditions for at least tw'o days preceding each test. 
,..., 
With x1 = 100 at fp = fp = FP and x1t = 25, Xlh = 175. 
The plasma FFA level declines to about 200 µEq/L a~er an 
infusion of a large dose of glucose or insulin. Assuming this to be the 
lowest possible value of plasma FFA concentration and further that 
gluconeogenesis saturates at this level, we obtain ~xl = 0.003 for a 
smooth variation over the specified range of 
1~ 1 <200 - r ) \ i:::; 2.0. x p 
f - that is, p 
Glucagon is known to increase gluconeogenesis from amino acids. 
Epinephrine increases gluconeogenesis by depleting muscle glycogen and 
increasing the availability of lactic and pyruvic acids to the liver. 
Since the present model does not include lactic, pyruvic and amino 
acids there is no logical way of separating the gluconeogenic effects 
of glucagon or epinephrine from its gl.ycogenol.ytic effects. In other 
words, if glucagon, for example, increased the glucose turnover by 
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t::;x. mg/min, there is no way of finding out what fraction of this came 
from gluconeogenesis. The parameters, axl' bxl' ax2 and bx2' 
associated with the increments of gluconeogenesis and glycogenolysis 
by glucagon and epinephrine were fixed by trial and error so as to 
obtain the reported glucose responses to IV injections of these 
hormones (see Figures 16, 17 and 18) 
(iii) Glycogenolysis: The glyocgenolysis rate, x2, is given by 
where 
The basal rate is about 50 mg/min as explained on page 30. 
In the simulation studies of subject 174 it was taken to be 45 mg/min. 
Under hypoglycemic conditions the plasma glucose concentration does 
not attain levels below 40 mg%. Therefore it is reasonable to assume 
that saturates at a plasma glucose concentration of about 50 mg% 
below nominal. That is, 
g = - 50 p 
gp2 is negative; its magnitude lies between 5 and 20. In the example 
of section 3.5, gp2 = - 10 and x2 ~ x2h at gp = - 40. ~xO is 
about O.Oh for a smooth variation - that is, l~xO E-4o - gp2) I ~ 2. 
Given o. f-'x2' and x 2(o), x2h can be computed. x2h = 200. As 
stated earlier, ax2 and bx2 were determined by trial and error to 
yield the responses shown in Figures 16, 17 and 18. 
where 
and 
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(iv) Glycogenesis: The glycogenesis rate, x5, is given byl 
x5h x5h 
x5 = ~ + 2 tanh [13x5 (x4 - ~4 F} 
The maximwn capacity of liver glycogen is asswned to be l25 gm. 
of equivalent glucose. Hepatic glycogenesis is stopped once the gly-
cogen level reaches this value. The factor O.OOl in the last equation 
above converts mg. into grams. In fact, this factor should be less 
than O.OOl in order to account for other hepatic pathways of glucose. 
However, there is no error since our experiments are conducted after 
an overnight fast; the glycogen level is low to start with (asswned to 
be So gm.) and it certainly cannot reach the ma.ximwn value even with a 
large glucose load of 30 or 35 gm. This means that the "glycogen switch" 
in Figure 4 is never open and consequently x4 = gp in all our experi-
ments. 13x4 is chosen so as to obtain the needed switch characteristic. 
13x4 = o.6 gives 
z_.(o) = So. 
'.) 
at Note that z5 = l25 and 
l The variable x truly represPnts the liver uptake of glucose to 
higher plasma gfucose concentrations. Since glycogen formation 
is the most predominant pathway in liver for glucose when it is 
being taken up, the term glycogenesis has been used. 
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Following Shames( 3) and Charette(Z) we will assume a maximum 
hepatic glucose uptake of approximately 700 mg/min. Insulin has been 
reported to increase the hepatic glucose uptake by a factor of about 
three~ SP F The upper physiologic limit of plasma insulin is around 
200 µU/me,. From these considerations, typical values for x5h and 
ax5 can be easily established. In our example, 
x5h = 250 + 2.5 (u1p - 9) 
Liver becomes a net sink for glucose at an absolute glucose 
concentration of about 150 mg%( 26 ) - that is, at gp ~ 50. Assuming 
saturates at g R:: 300, p can be determined. 13x5 is 
chosen to yield a smooth variation over the range of x4. In our 
example, 
The maximum rate of glycogenolysis when glucagon and epinephrine levels 
are at their peak (about 4 and 1.1 ng/ml respectively) is approximately 
2000 mg/min. It is noteworthy that it is roughly three times the 
maximum glycogenesis rate as calculated by Charette~ O F 
(v) Renal excretion: The renal excretion rate, x6, is given by 
where K = Slope of the renal excretion function when g >> g 6 • r p p 
t3 ,. = o.4 gives x6 ~ 0 at g = g 6 - 10. 
xb p p 
150 m-%. (Z) K can be t· t tS7° r es ima ed by measuring the 
is around 
a.mount 
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of glucose excreted in the urine after an IV glucose tolerance test. 
In the example of section 3.5, 
K 
r 
= 2.2 
l30 
(vi) Muscle utilization: The rate of glucose uptake by muscle, 
x8, is given by 
where 
y5 = Muscle oxidation of FFA 
The glucose turnover rate under basal conditions is in the 
vicinity of 150 mg/min. A reasonable figure for brain utilization is 
80 mg/min~ STF Assuming an utilization rate of 100 mg/min by the CNS 
and RBC, 50 mg/min is utilized by the peripheral tissues under basal 
conditions. We will assume that about 40 mg/min is consumed by muscle 
and the balance by adipose tissue. Andres et.al.( 67) have reported 
22 mg/min by skeletal muscle and 14 mg/min by heart under basal condi-
tions, giving a total of 36 mg/min. Since ~~r~iac muscle is not 
separately included in our model, a value of 40 mg/min for basal muscle 
uptake of glucose seems very reasonable. 
As mentioned earlier, the maximum physiologic concentration 
of plasma insulin is about 200 µU/ml. With the insulin degradation 
para.meters indicated on page U~ this implies a maximum interstitial 
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insulin concentration of 100 µU/mt. It is reasonable to assume that 
the peripheral glucose utilization saturates at about this level of 
interstitial insulin. This implies ~li ~ 50. A maximum glucose uptake 
of 2.5 mg/lOOmt forearm/min by forearm muscle has been reported by 
Christensen and lrskov~ PTF This indicates a muscle uptake of (25)(35) = 
875 mg/min for the whole body assuming a muscle mass of 35 kg. and that 
the measured forearm volume consisted entirely of muscle. The latter 
assumption is not quite true. Furthermore uptake by cardiac muscle has 
not been included. Hence a value in the vicinity of 1000 mg/min would 
seem more reasonable. 
Given uli' 
example of section PK~ 
x8h = 1160 
u1i = 34.5 
x8 (o) = 37.8 
t3x8 = 0.0565 
t3x8 
1 
can be computed. In the 
Since cannot become negative under any circumstances, 
The maximum value for (y5 - Y5 ) is about 250. This gives an estimate 
of 
1 
ax8· ax8 = 4.o for subject 174. 
Yii is the fasting value of u .• It can be calculated knowing 
UJ.:p and the degradation paramet~rs of insulin. 
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(vii) Adipose tissue utilization: 
There are no data available in the literature from which a 
value for x9h can be obtained. In the simulation studies it was assumed 
to be same as x8h. Considering the fact that in a normal 70 kg. man 
adipose tissue mass is only about one-third of muscle mass, this implies 
that the maximum gluocse uptake per kg. of adipose tissue is 3 times 
higher than the maximum uptake per kg. of muscle. Furthermore is 
assumed to be the same as for muscle. ~xg is computed as before. 
example, 
In our 
= ll60 
= 34.5 
x9(o) = 8.4 
13xg = 0.082 
It is noteworthy at this point that assumptions such as 
x8h = x 9h are aimed at reducing the r<umber of unknown parameters, if 
it is possible and physiologically consistent. This will greatly 
facilitate identification of parameters based on available limited data. 
The idea here is to obtain a simple representation, yet detailed enough 
for our purposes. 
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Models for hormone controllers: 
(i) Insulin controller: The equations are: 
The plasma and interstitial fluid volumes are assumed to be 
known. V =3.5L and V. =10.5L. p 1 KJ.i and KJ_2 can be 
estimated from the insulin response data following an IV infusion of 
insulin. Since these data were not available in the case of subject 174, 
the parameter values were chosen to conform with the observations of 
Orskov and Christensen( 6B) with exogenous insulin and those of Samols 
and Marks( 69) on endogenous insulin. 
KJ.o = 0.3 
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'l'he associated time constants1 are 4.4 and 21.0 minutes. The values 
of is_0, K11 and is_2 for subject 174 are roughly same as those for 
subject B. The latter were based on insulin response data (see Figure 
12) taken on the subject following adminstration of lU of insulin. 
Knowing is_0, is_1 and is_2, the para.meters associated 
with insulin secretion functions, and wll' were adjusted to 
fit the insulin response obtained during an IV glucose tolerance test. 
Properly designed systems experiments can yield the necessary infor-
mation to estimate these parameters reasonably accurately. The reader 
is referred to Charette's thesis( 2) for a further discussion on this. 
As noted on page 37, w1ot was taken to be nonzero. It was, however, 
made very small. Similarly w1l f. o. This implies that epinephrine 
does not completely shut off the pancreatic secretion of insulin. w1l 
can be easily computed with the knowledge of 1S.O' is_1 and is_2 and 
the steady-state plasma insulin concentration during a prolonged epine-
phrine infusion experiment like the one performed by Porte et.al.(5l) 
l 
where 
If Al and A2 are the reciprocals of the time constants, they 
are given by 
Al 2 
al + a2 
= 
' 
2 
KlO + 
al = v p 
4~O 
y = v v. p 1 
~ 
-J<a1 
2 
± 
- a ) + y 2 
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In our example of section 3.5, 
wlOh = 58.0 wlOt = 3.9 
f3wl0 = 0.02 ; gpul = l20 
wllh = 67 .o . f3wll = 0.2 , 
...., 
z2ul = J.5 wl-l = 3 .o 
f3wl = 20 u3p = 0.4 
The secretion of insulin is practically zero for plasma 
epinephrine levels higher than 0.5 ng/ml. The net Secretion rate under 
fasting conditions = wl0 (o) + wll(o) = wl(o). It should correspond 
to the measured fasting concentration of insulin. It is noteworthy 
that the maximum secretion rate = 58 + 67 = l25 corresponds to a 
plasma insulin level of 250 µU/ml which is in the vicinity of the 
upper physiologic limit. 
(ii) Glucagon controller: The equations are 
K2 was chosen based on the observations of Samols et.al. (
43) 
v 
K 2 0 Th t . t t e l4. 0 0 . t 2 = • • e lllle cons an = K2 
= ~ = 7. ml.Im es • 
Glucagon, epinephrine and GH are released under hypoglycemic 
conditions. Maximum secretion of these hormones would be expected 
before hypoglycemia reaches dangerous proportions, i.e., before plasma 
glucose declines by more than 50 JJJft'/o. We can choose g 2 based on pu 
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this argument. w2h corresponds to the maximum physiologic concentration 
of glucagon - about 4 ng/mt~ToF The fasting concentration and the de-
gradation constant determine the value of w2(o). Given w2(o), w2h 
and gpu2' ~wO can be calculated. For subject 174, 
gup2 = - 20 
~wO = 0.061 
(iii) Epinephrine controller: The equations are: 
w30h w30h 
W = - - - tanh [A (g g...., ) } 30 2 2 f-'w30 p - pu3 
The choice of ~ was based on the epinephrine response 
reported by sendsalu~ SlF v e 14.o ~ = 9.0. The time constant = ~ = 9•0 
= l.55 minutes. gpu3' w30h and ~wPM are chosen in the same way as 
glucagon secretion parameters. It should be noted that in this case 
w30h does not correspond exactly to the maximum physiologic concent-
tration of epinephrine (about l.O ng/ml). For subject 174, 
= - 20 
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= 10.06 
~wPM = 0.058 
There are no physiological data which would help choose the parameters 
associated with w31 • One would expect w3lh < w30h. 
We will assume 
~OuP = - ~Oul as a first guess in view of the fact that epinephrine 
and insulin act in opposite directions in several respects. ~wP1 is 
selected to yield a smooth nonlinear function. For subject 17!1, 
~wP1 = 0 •3 
(iv) GH controller: The equations are: 
w4h w4h 
w4 = - - - tanh ro (g g"' ) } 2 2 li-'w4 p - pu4 
The choice of K40, K41 and K42 was based on the reported 
response to r:v growth hormone injection by Parker etKal~TlF 
K40 = 0.035 
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The time constants are 7.7 and 35.5 minutes. The secretion parameters 
are chosen as explained for glucagon and epinephrine. Maximum physiol-
ogic concentration of GH is of the order of 50 ng/mt~TO F The parameters 
in our example are: 
,..., 
g 4 = - 20 pu 
w4h = 13 .26 
t3w4 = 0.095 
1 FFA Model : 
(i) Distribution: A single compartment with a volume v = v + v. e p i 
= 14.0L is assumed. Since FFA are known for their very short half-life 
of 2 to 4 minutes in plasma(46 ), T5 < 5 seems reasonable. T5 = 2 for 
subject 174. It is indicated in the next chapter that T5 is not a 
highly sensitive parameter. 
(ii) FFA utilization: The rate of oxidation of FFA by muscle is 
denoted by the symbol y5 • It is linearly dependent on concen-
trations of epinephrine and growth hormone. If Y5 is the basal rate, 
we have 
u4i can be readily calculated given the degradation and diffusion con-
stants and plasma concentration of GH. 
1 
The turnover rates of FFA in fasting subjects at rest and 
Chapter 4 is devoted to procedures and algorithms for systematically 
identifying the parameters of the proposed FFA model. 
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during exercise have been measured by several authors~TF In healthy 
individuals it lies in the range 400-900 µEq/min after an overnight 
fast of about 12 hours. The value assumed for subject 174 is 700 µEq/min. 
Approximate1¥ 33% of FFA turnover undergoes immediate oxidation in both 
lean and obese subjects~4TF Assuming a liver oxidation (both complete 
oxidation of co2 and H2o and partial oxidation to ketones) of 
140 µEq/min and a total of 240 µEq/min and neglecting the flux of FFA 
from plasma back to adipose tissue (see page 41), Y5 = 240 - 140 = 
100 µEq/min. The values given for and are first guesses. 
by5 was made large enough to obtain the desired initial dip in the FFA 
response following an IV dose of GH (see Figure 19). 
~ and ~ associated with utilization functions y6, y7 and 
y8 were chosen to be same for the sake of simplicity. With the addition 
of TG and ketone loops, systems experiments can be designed to give in-
formation regarding the detailed behavior of these functions. 
- Y9h + y9t Y9h - v9~ tanh "' 
- 2 + 2 E~v9 (fp - fp)} 
Y9 = Fasting value of y9 
y 9h + y 9t . "' 
= 2 if fp = Fp' fasting plasma FFA level 
f was assumed to be same as F for reasons indicated on page 81. p p 
~y9 was chosen assuming a variation in plasma FFA concentration of 
± 400 µEq/L about its fasting value. For subject 174, 
~y9 = 0.005 
y9 = 700 - 100 = 600 
YS = 140 
y = 70 7 
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y6 = 600 - (140 + 70) = 390 
Carlson and Ekelund(73) estimate a hepatic uptake of roughly 10 mEq/hr 
for oxidation and less than 5 mEq/hr for net transport to the periphery 
as m. Based on their estimates, our figures for Y8 and Y7 
seem 
re as enable • The saturation levels of and y8 had to be 
guessed since there are no physiologic data to base their choice upon. 
(iii) Effects of insulin: The equations are: 
The proposed FFA model assumes that the mobilization of FFA 
under fasting conditions is entirely due to diminished insulin levels 
(see page 48). Therefore 
Yloh ~ Y1, lipolysis rate due to insulin under basal conditions 
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~ Basal FFA turnover rate 
A value of 680 was used in the example of s~ction 3.5. 
The plasma concentrations of epinephrine and GH decline and 
stay very low during the initial phase of an DI glucose tolerance test. 
The decrease in plasma FFA level is therefore entirely due to elevated 
levels. of insulin in our model. The FFA response characteristically 
exhibits a sharp decrease followed by a plateau {see Figures ll, 14 and 
15). Since essentially steady conditions prevail in the flat region of. 
the response, ylot should be very nearly equal to the FFA utilization 
rate corresponding to the FFA concentration in the flat portion. Thus 
Ylot = 425 for subject 174. The fast decline in FFA level requires 
jz12{o) - ~1O 1 < 10. After choosing z12, t3ylO can be calculated to 
obtain a smooth variation. For subject 174, 
t3yl0 = 0.745 
z12 was chosen to be o.46 in our example after observing 
the range of ~1O in a few trial runs. yllh' and 
chosen to fit the initial fast decline of plasma FFA concentration. 
It should be noted that y11 ~ 0 for ~lO < o and hence y11 contrib-
utes only in the initial phase. 
(iv) FFA release by epinephrine: The equations are: 
u ' 3P 
-97-
u ' 3P 
An est:ilnate of gi can be obtained from the value of plasma 
glucose concentration at the instant at which the plasma level of FFA 
begins to drop during a prolonged epinephrine infusion experiment. 
is chosen such that u....' ~ u3 for g. > g. + 10. jp p ]. ]. Since the 
maximum physiologic concentration of epinephrine is about 1.5 ng/ml 
tt3p lies in the range 0.0 - 0.8; that is, lu3p(o) - u3pl < 0.8. 
~yO was selected to yield a smooth variation over the range of epine-
phrine concentration. Y2h was chosen by trial and error to give the 
required peak FFA concentration obtained during J:I/ epinephrine infusion 
tests (Figures 17 and 18). In our example, 
Since can never become negative, 
Assuming (u3 ') = (u3 ) = l.o, p max p max ay2 < Y2h • ay2 = 490 for subject 
(v) FFA release by GH: The equations are: 
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The para.meter values were mostly determined to obtain the re-
quired FFA responses following IV injections of GH and insulin (Figures 
~ 
19 and 20). It was found that z13 should be less than 15. As before, 
~vP was chosen such that l~yP (z13 {o) - i 13 JI ~ 2.0 which ensures a 
smooth variation. 
I , 
,, II I I ' 
Ii 
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IV. ESTIMATION OF PARAMETERS OF THE PROPOOED FFA MODEL 
4.1. Introduction. 
A hypothesized model is not very useful unless methods and 
procedures are provided for estimating the parameters of the model. The 
problem of determining the numerical values of the parameters of a given 
model by suitably process mg the data that can be obtained on the stimuli 
and the associated responses is the so-called "inverse problem". The 
inverse problem is far from trivial even from a strictly theoretical 
point of view and is often complicated by "observability" requirements. 
One has to make sure that the stimulus-response data contain enough 
information about the unknown parameters and that the response to a 
given stimulus is reasonably sensitive to changes in the values of the 
associated parameters. 
The aim of this chapter is to demonstrate how certain techni-
ques well-known to systems engineers can be readily employed to identify 
the parameters of the proposed FFA model. Charette( 2) has already con-
sidered the identification of parameters associated with the glucose 
and hormone controller models. Attention is therefore focussed here on 
only the FFA portion of the proposed model. The results are intended to 
further illustrate the feasibility of the systems approach to modeling of 
biological systems. It is shown that despite the complexity of our 
model, it is possible to estimate the parameter values by suitably pro-
cessing the stimulus-response data obtained from certain specific 
physiologic systems experiments. 
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4.2. The General Approach. 
It is a formidable task to estimate simultaneously all the 
unknown parameters in a given model even if the required data on the 
stimuli and responses are available. However, by using specific portions 
of the available data, the parameters associated with specific portions 
of the model can be identified. Such possibilities are revealed by an 
analysis of the hypothesized model. 
For example, infusion of a physiological dose of GH does not 
appreciably affect the levels of glucose and other hormones (insulin, 
glucagon and epinephrine) included in our model. There is a delayed but 
highly significant rise in plasma FFA concentration. The subsystems 
involved are the following: dynamics of FFA release by GH, FFA distribution 
in extracellular space and the various utilization pathways of FFA. The 
parameters associated with these subsystems can be identified using the 
data on FFA following an IV GH injection. The remaining part of the model 
does not enter the picture and can therefore be ignored. On the other 
hand, IV infusion of insulin causes almost all the variables in the model 
to vary appreciably. Hence the data obtained after insulin injection 
cannot be easily used. 
In the sequel, physiologic systems experiments are proposed 
and algorithms are developed for estimation of parameters in the FFA 
model. Reliance is placed on tracer techniques!74) well-known to life 
scientists, for obtaining certain steady state information. The entire 
model is identified by a sequence of identification problems, each in-
volving estimation of not more than five parameters. Parameters already 
identified are, of course, assmned to be known in the subsequent identi-
fication problems. The algorithms are based on a modified version of 
-101-
the quasilinearization method~TRITSI O F The fact that many of the physiol-
ogic para.meters vary over o~ a limited range is fulJ.y exploited. The 
method does not require any statistical description of measurement errors. 
The criterion used is least-squares. The approach, it should be noted, 
is non-sequential, thus permitting canputations to be done off-line. 
The example of Section 3.5 is used to produce artificia~ the 
required experimental data. The true or ideal response for any given 
stimulus is first generated by integrating the model equations with the 
para.meter values indicated. The data thus obtained is deliberately 
corru~ted with noise to simulate the laboratory measurement errors. The 
resultant data along with guessed values for the unknown parameters are 
then used in the estimation algorithms. The following noise model is 
used to corrupt the data on FFA which is the o~ one of interest to us. 
where 
f ( t.) = f ( t.) + TJ( ti) pc 1 p 1 
= f (t.) + Mr p 1 
f (ti) = Observation at time t. (µEq/L) pc 1 
f P(ti) = True value of plasma FFA concentration at time 
ti (µEq/L) 
= Observational error at time ti 
M = Maximum possible error (µEq/L) 
r = Uniformly distributed randan variable in the 
range [-1, +l]. 
(4.1) 
The largest value of M used is 30. This implies an error of '35°/o at 
-102-
a FFA concentration of 600 µEq/L; it is ± 1.5% when the FFA level is 
2000 µEq/L. The figures are reasonable considering the fact that 
methods are now available to measure FFA concentration within errors 
less than 2%, especially at high concentrations. 
The identification problems presented in Section 4.4 assume 
that.the proposed FFA model is a valid representation of the human 
metabolic control system. It is certainly not the ultimate model and 
needs further improvements. The missing loops such as amino acids and 
'IU and hormones such as glucocorticoids are to be included. It is there-
fore emphasized that the estimation algorithms presented here are not 
aimed at obtaining the final answers. The more important point is the 
approach; the results are intended to further illustrate the potentiali-
ties of the systems approach in modeling of biological control systems. 
4.3. The FFA Model Equations. 
In terms of symbols and definitions of Sections 3.5 and 3.6 
the equations of the proposed FFA model are the following: 
Y1oh + Ylot 
=--~---2 
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l + tanh (13 3 (g. - g.)} U 1 =U Up J. J. 
, 3P 3P 2 
Y2h = Y2h - ay2 uP~ 
y2h Y2h ~ 
y2 = ~O~ + '"2'""' tanh (13y2(u3p - u3p)J 
(4.2) 
There are 27 unknown parameters in all. They .are: 
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Ve ' T5 
y5 ' ay5 ' by5 ; Y9h ' y9t ' ~y9 ' fp 
'>' 
T3 ' Y1oh ' Y1ot ' ~yll ' zl2 ; yllh ' ~yll , zl2 
,.., 
~uPp ' gi ; y2h ' ay2 ~yO , ~p 
,.., 
T4 ' Y3h ' ~yP ' zl3 
The following are assumed to be known in the identification 
problems discussed in the next section: parameters associated with hormone 
controllers1 ; fasting levels of FFA and all hormones; the extracellular 
volume, V ; the oxidation (innnediate) of FFA under basal ccnditions 
e 
= y5 + Y8; the turnover rate of FFA under fasting conditions= Y4 = Y4
1
• 
The turnover rate and the amount utilized for direct oxidation ean be 
estimated by tracer techniques~TTI 4TF Furthermore, as indicated on 
page 81, it is assumed that 
..., 
fp = Fp' the fasting plasma FFA concentration. 
4.4. The Identification Problems 
The following three experiments were found to be adequate for 
the estimation of the unknown parameters of the FFA model. Only the 
observations needed for the identification of FFA model parameters are 
listed. The figures given for infusion rates, sampling instants etc. 
are only representative figures. They were used in generating the re-
quired experimental data by simulation on the computer. The units of 
time, concentrations, rates etc. are the same as given in Section 3.5. 
1 
Experiment #1: Prolonged IV epinephrine infusion. 
Input: IV epinephrine at a constant rate of 6 µg/min for a 
See reference 2 for identification of para.meters associated with 
hormone controller models. 
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period of 200 minutes until steady state conditions 
are established~ 
Observations1 : 
(i) Pl.asma FFA concentration at t = 01 31 61 ••• ,18,21, 
25, 30, ••• '65' 70, 80, 90 ••• 190, 200. 
(ii) Plasma glucose concentration (continuous mea-
surement) 
(iii) Basal oxygen consumption, <\,; oxygen cons um.pt ion, 
<\n' and FFA turnover rate, Y4n' after establishment 
of steady state condtions with constant epinephrine 
infusion. 
Experiment #2: IV growth hormone infusion. 
Input: 1000 . IV growth hormone at a constant rate of ~ µg/min 
for a period of 3 minutes. 
Observations: Plasma FFA concentration at t = 0,10,20, •••• , 
120, 130. 
Experiment #3: IV glucose tolerance test. 
Input: IV glucose at a constant rate of 10 g/min for a 
period of 3.5 minutes. 
Observations: Plasma FFA concentration, at t = 01 5,10 ••• , 
35, 4o, 50, ••• , 120, 130. 
It is necessary to establish first the numerical values of the 
para.meters associated with FFA utilization. It would be easier to 
estimate them if FFA can be directly injected into the blood. Unfort-
1 Bl.ood requirement of 2 cc for each FFA measurement and 15 cc for 
one hour of gl.ucose measurement is assumed. 
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1 
unately this cannot be done • The observations listed under experiment 
#1 above are intended to facilitate the identification of FFA utilization 
parameters, as will become evident from identification problem #1 dis-
cussed later. 2 Now let 
1 
2 
P1 = zl5 = f P = Plasma FFA concentration 
pl 
dpl 
P2 = = dt 
,.., 
P1 = f p 
The equations describing the changes in p1 and p2 are: 
P1 = P2 
(4.3) 
Direct infusion of large amounts of FFA has adverse reactions such 
as haemolysis, thrombosis etc. A special infusion technique which 
is free of adverse reactions has recently been reported by Greenough 
and Steinberg(78).They successfully performed it on dogs(79). 
Recall that a small letter is used to denote a variable and the 
corresponding capital letter its fasting value. 
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,.., 
Since we assume p1 = fp = Fp' fasting plasma level of FFA, 
Therefore, Eqs. (4.3) become 
P1 = P2 
Ve(T5P2 + P2)= (b.yl + cy2 + 6Y) - (ay5(u3P - U3P) + by5(u4i - U4i)} 
(4.4) 
where 
Consider the continuous DI epinephrine infusion experiment 
indicated earlier. Since insulin and growth hormone levels are not 
affected much we can ignore the terms 6y1, 6y3 and by5(u4i - u4i) from 
the right hand side of Eqs. (4.4). The term ay5 u3P can be neglected 
since the fasting concentration of epinephrine is usual]¥ ve-ry small 
compared to the concentrations attained during a continuous infusion 
of epinephrine at a rate of 6 µg/min. Furthermore, the contribution of 
FFA release by epinephrine is small under fasting conditions. Hence 
ey2 F:::Jy2 • With these approximations the following equations pertain 
to experiment #1. 
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(4.5) 
where 
It should be noted that the terms neglected in the above 
equations, a U and 
Y5 3P have a 
cancelling effect. Epinephrine infusion causes insulin level to slight}¥ 
decrease and GH level to slightly decrease. The latter is due to the 
increased glucose level caused by the glycogeno}¥tic and gluconeogenic 
effects of epinephrine. Hence cy1 is positive and cy-3 is negative 
and they tend to cancel each other. 
Next consider the second experiment -·GH infusion. There is 
little change in the levels of insulin and epinephrine? The same kind 
of approximations ma.de in Eqs. (4.5) lead to the following set of equa-
tions pertaining to experiment #2. 
Pi = P2 
Ve(T5p2 + p2 )= y3 - by5u4i - aY9 tanh [~v9 (p1 - p1 )} 
= ay3 + ay3 tanh [~vP EpP - p3 )) 
T4p3 + P3 = u4i (4.6) 
where 
"' 
...., Y3h 
P3 = zl3' P3 = zl3 and ay3 =-2 
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A similar set of equations (except for an additional term) 
hold in the case of experiment #3. 
P1 = P2 
Ve(T5P2 + P2)= aylO + aylO tanh f~y1o<mP - P3)} 
(4.7) 
where 
yllh 
a =-yll 2 
Eqs. (4.7) are valid only as long as the levels of epinephrine 
and GH are low. The plasma glucose level typically undershoots a little 
after about 60 minutes in an rv glucose tolerance test. Under these 
circumstances epinephrine and GH are released. However, the increase 
in their levels is small since the hypoglycemia is very mild. Consequently 
their effects on FFA metabolism can be neglected. Moreover these effects, 
namely, increase of lipolysis and muscle FFA oxidation, tend to cancel 
each other. We will therefore assume that Eqs. (4.7) are valid over the 
entire period of observation of approximately two hours for experiment #3. 
We will make a further simplification at this point. We will 
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assume that the time constant, T5, associated with FFA distribution is 
known. This is justified by the fact that the FFA response is relatively 
insensitive to changes in T5 • The maximum deviation obtained using 
Eqs. (4.4) and a constant input1 was less than 1% when T5 was varied 
over its normal range (l-5 minutes) with all other parameter values un-
changed. It can therefore be chosen based on the results of a tracer 
experiment. The rest of the parameters of the FFA model are identified 
in a sequence of five identification problems discussed in the sequel. 
The input and the data required are indicated in Figures 21, 22 and 23. 
Identification problem #l: 
Pa:nameters identified: 
Observations required: 
(i) Experiment #l; plasma FFA concentration at 
t = 40,45, ••• ,65,70,80, ••• ,190,200. 
(ii) Observations (ii) and (iii) in experiment #l 
(see page 105). 
The parameters identified first are gi and ~uPpK With the 
type of epinephrine infusion2 indicated in Figure 21, attains a 
steady value in about 25 minutes, i.e., in about 10 minutes after the 
infusion rate is made steady. y2(u3p) is constant for approximately 
l The term (ay5(u3P - u39) + by5(u4i - u4i)} was discarded. (t:.y1 + 
6Y2 + t:.Y3 ) was replaced by a constant. Values of ay9' ~v9 and p1 
for subject 174 were used. 
2 Infusion is steadily increased in steps in order to increase the 
observability of the parameters identified in problem #2(see Page 
ll8). 
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Figure 22. FFA Data for Identification Problem #3. 
Input is 1 mg of GH given intravenously at a 
constant rate over 3 minutes. 
130 
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Figure 23. FFA Data for Identification Problems 4 and 5. 
Input is 35 gm. of glucose given intravenously at a 
constant rate over 3.5 minutes. 
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25 < t < 45. At about 45 minutes the interstitial glucose concentration 
begins to reduce the FFA release rate y2 • One can estimate fr am 
the value of plasma glucose concentration at the instant at which the 
. 
plasma level of FFA begins to fall, i.e., f = O. Denote this instant p 
by t • t can be figured by drawing a smooth curve through the ob-
c c 
served values of FFA concentration from t = 40 to t = 70. 
be.the plasma glucose concentration (deviation from nominal) at 
g. is slightly less than g for the following reasons. (i) There is 
1 p 
a continuous movement of glucose from plasma into the interstitial space 
due to the glycogenolytic and gluconeogenic actions of epinephrine in 
the liver. (ii) The inhibition of FFA release must have been initiated 
a little while before 
I g. = g - 6 
1 p 
' gp became equal to gp. 
where 6 is about 5 mg%. 
Thus 
(4.8) 
From the simulated data the true value of g' is 63 mg°/o. p 
Allowing :I: 2 mg°fo for measurement errors, the observed value of g' p 
lies between 61 and 6 5 mg°/o. Therefore the estimated value of g. = 
1 
( 58 ± 2) mg°/o, if 6 = 5 mg°fo. The actual value is 58 mg°/o. The es tima ti on 
error is very small indicating that no sophisticated estimation technique 
,.., 
need be employed for identif'ying gi. 
13u3p is not a critical parameter. Any value in the range 
0.2 - o.4 is a good estimate.of 13u3p. If 13u3p = 0.2, ~~ F:d u3P 
,.., 4 ' ,.., 
when gi > gi + 10; if 13u3p = o. , u3p ~ u3p when gi > gi + 5. 
It remains to estimate the parameter values of aY9' 13Y9 and 
ay5• To this end, we will ma.ke use of the fact that the inhibition of 
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FFA release is complete and y2(u3P) is constant for t > t + 10, c 
gi > gi + 10. If u;: is the steady state concentration of u3P under 
the constant rate input? 
(4.9) 
Thus for t > tc + 10, we have a constant but unknown input acting 
upon the distribution and nonlinear utilization mechanisms of the FFA 
model. I.et c1 denote this constant input. Then, referring to 
Eqs. (4.5), 
c1 = y2(u;:) - ay5 u;: (4.10) 
An approximate value for c1 can be obtained from the mea-
surements of rates of FFA turnover and oxygen consumption under basal 
conditions and after establishment of steady state conditions with a 
constant IV epinephrine injection. 
where 
(4.ll) 
Y4, ~ = Basal rates of FFA turnover and oxygen consumption 
respectively. 
Y4n,obn= Rates of FFA turnover and oxygen consumption respect-
ively after establishment of steady state under 
epinephrine input. 
K = Oxygen required/µE q of FFA. 
0 
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There are two assumptions involved in the second approximate equality 
above. 
(i) Under a constant infusion of epinephrine the extra oxygen 
consumed is entirely due to increased FFA oxidation. There may however 
be contributions from other substrates. 
(ii) The increased FFA oxidation takes place only in the muscle, 
SS the term ay5 u3p accounting for all of it. A small contribution by 
the liver as indicated by the equation for y8 on Page 78 is neglected. 
It can be positive or negative depending on the new steady state value of 
plasma FFA concnetration. There may also be a contribution from adipose 
tissue. However, our assumption is justified by the fact that catecho-
lomines are the stimulators of large amounts of energy mainly in the form 
of FFA to the working muscles during exercise~UMI UlF 
The above assumptions imply that the error is on the higher 
side in the estimation of ay5 u3;s; or equivalently it is on the lower 
side in the estimation of c1 • However, we will proceed under the 
assumption that is known approximately. The parameters ay9 and 
~y9 are to be identified, given e1 • We will make use of the observa-
tions on plasma. FFA concentration in the interval [80, 200] in experi-
ment #1. The problem is then the following: 
System: If the initial time corresponds to t = 80 in experiment 
#1, we have, for 0 ~ t ~ 1201 
1 Initial conditions are unknown and are treated as unknown parameters. 
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Observations: Number of observations, N = 13. 
f (t.) =p1 (t.) + 'T)(t.) pc i i i 
t. = 0,10,20 
i 
... 110,120. 
Known Parameters: Ve' T5, c1, Pl 
Unknown Parameters: a.Y9' ~v9D p2 ( o), Pi ( o) 
13 
Performance index: J = [ 
i=l 
{f (t.) - pl(t.)}2 pc i i 
(4.12) 
Estimate the unknown parameters so that J is minimized. 
p1(t) represents the estimated solution p1 (t) using Eqs. (4.12). 
The unknown parameter t3Y9 varies between O.OOl to . 0.01. 
If t3Y9 = 0.0001, y9 saturates for fp > Fp + 100 and if t3Y9 = 0.01, 
it saturates for fp > FP + 1000. For a given value of t3y9' ay9 can 
SS be readily computed knowing c1 and p1 , the new steady state con-
t t . f FF ' la l cen ra ion o 'A in p sma • 
l 
It remains to identif'y p2(o) and p1 (o). They are identified 
When the successive measurements lie within experimental errors, one 
can assume that steady state has been attained. By taking the aver-
age of the last two or three measurements the error in the measure-
t f SS b • . • d men o p1 can e minimize • ss ,..., 
a cannot be calculated if pl = p1, i.e., if the new stea~tate level of FFA is same as the fasting level. This implies 
that the increased mobilization and utilization of FFA exactly 
balance. The experiment will have to be repeated with a different 
dose of epinephrine. 
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via the method of quasilinearization. The a14?;orithm starts with the 
largest possible value of ~y9D namely O.Ol, computes the corresponding 
value using Eq. (4.13) and then finds out the values of p2(o) 
and that minimize J. 
0.009, 0.008, •••• until J 
The procedure is repeated with ~y9 = 
is minimized with respect to ~y9 • The 
entire a14?;orithm is repeated for several values of c1 and the minimum 
with respect to c1 is chosen. The computations need be done only for 
a few values of c1 since its value is known approximately. The re-
sults are tabulated in Table 4. The initial guesses for p2(o) and 
p1 (o) are obtained by drawing a smooth curve through the observations, 
f (t.), and finding out its initial value and slope. pc J. 
We can now estimate 
It is noteworthy that the 
allow us to estimate 
from Eq. (4.lo). 
(4.14) 
above estimation procedure does not 
_ Y9h + y9f, We need to know Y
9 
- - 2 ~ 
in order to compute y9h and y9l. It does not matter, however, since 
this information is not needed in studies of dynamic characteristics. 
Identification problem #2: 
Parameters identified: Y2h' ~yOD u3p' ay2 
Observations required: 
Experiment #1; plasma FFA concentration at t = 0,3,6 ••• 
18,21,25,30,35,40. 
The inhibition of epinephrine-induced lipolysis by interstitial. 
glucose concentration is not present till approximately 
where tc is the instant at which the plasma FFA level begins to fall 
Maximum 
Error 
M 
15 
30 
Table 4. 
c1 
Estimated Values Performance 
VeT5 
Index 
ay9 
pl(O) p2(o) VeT5 8Y9 J/N 
3,3 1465.5 -12.95 7 .673 0.004 100.17 
4.3 1465.5 -16.10 8.285 0.005 85.97 
5,3 1465.6 -24.23 8.863 0.006 128.32 
3,3 1473.0 -16.49 7.673 0.004 318.81 
4.3 1473.0 -19.77 8.285 0.005 314.41 
5,3 1473.1 -27.29 8.863 0.006 369.54 
Estimation of cl' ay9 and By9 . 
True values: C/VeT5 = 4.o ; ay 9/v eT5 = 8. 58 ; By9 = 0.005 
Initial guess: p2(0) = -9.0 ; pl ( 0) = f ( 0) pc 
+ Minimum 
+ Minimum 
pl(O) = 1458.0 
I 
~ 
\.0 
I 
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(see Page ll4). Hence in the observations interval [0,40], ~~ = O and 
y2h = Y2h (see Eqs. (4.2)). If u3P is the plasma epinephrine concen-
tration and Y2 is the FFA release rate by epinephrine under fasting 
contidions, 
Recall that the contribution of Y2 to the fasting FFA turn-
over rate, Y4, was assumed to be small in the construction of the FFA 
model (see Page 48). Consequently Y2 is only a small fraction of 
Y2h which is of comparable magnitude to Y4 • This implies that 
tanh (A (u u )} is close to 1. Let 1-'y2 3P - 3P 
l3y2Cu3p - u3P) = c2 (4.16) 
The above relation is used in identifying the para.meter values of Y2h, 
13y2 and u3P. 
only 5°/o of Y2h. 
It is assumed that is 
"' Furthermore the range of u3p is limited. When u3
p = o, 
y2 ~ 0 and when u3p = 3, the upper physiologic concentration of epine-
"' phrine in plasma, y2 ~yOhK This suggests that the range of u3p is 
0 - 1.5. The identification problem is then the following: 
System: The initial time corresponds to t = O in experiment #1. 
We have, for O ~ t ~ 4o 
P1 = P2 
y2h 
Ve(T5p2 + p2)= -a-- (1 + tanh E1PyO E~m - u3P)}] 
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(4 .17) 
u3p(t) can be easily computed knowing the epinephrine input 
and degradation constant. If I 3 is the input and ~ is the degrada-
tion constant, 
. 
Ve u3P + ~ ~p = I3(t) (4.18) 
The fasting level of epinephr :ine is ignored in this calculation since 
the endogenous secretion of epinephrine declines as the plasma level of 
glucose is increased by its glycogenolytic and gluconeogenic effects. 
Initial Conditions: 
p1 ( o) = F p' fasting plasma FFA level. 
p2 (o) = 0.0 
u3p(o) = 0.0 
Observations: Number of observations, N = 12 
f (t.) = p1 (t.) + 'T)(t.) pci i 1 
t. = oIPIS~···I1UIO1IORIPMIPRI4M ]. 
Note that f (o) = p1 (o) = F, assuming noiseless measurement •. pc p 
,.., 
Known parameters: Ve' T5, aY9' 13Y9' P1, ay5 
,.., 
Unknown parameters: Y2h' 13y2' ~p 
12 
Performance index: J = 2:: (fpc(ti) - p1 (ti)) 2 
i=l 
Estimate 'the unknown parameters so that J is minimized. 
p1(t) represents the estimated solution p1 (t) using Eqs. (4.17) 
and (4.18). 
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13y2 is The algorithm starts with the largest value of 
computed using Eq. (4.16) for a given value of c2 > l.5. is then 
estimated via the method of quasilinearization. J is minimized with 
,.., 
respect to u3P by decreasing u3P in small steps. A coarse search 
followed by a finer one reduces the computation time. The entire algor-
ithm is repeated for several values of c2 and the minimum with respect 
to c2 is chosen. Changes in c2 were not made automatic in order to 
reduce the computation time. Since c2 > l.5 and furthermore any value 
of c2 > 3.0 would result in a switch-type function for FFA release by 
epinephrine, the range of c2 is limited. Thus the algorithm need be 
used only for a few values of c2 • The results are shown in Table 5. 
Remark: It should be noted that the minimum values of J were 
obtained with c2 = l.5. In fact, lower values of J resulted in some 
runs with c2 < l.5. The difficulty here is due to the fact that both 
13yz and u3p are not observable with the given observations. In other 
words more than one set of values for Y2h' 13y2 and u3p can be found 
to fit the given observations. Hence the restriction c2 > l.5 is 
imposed. This conforms with the way the model was constructed. The 
most sensitive parameter here is Y2h. Our identification procedure 
makes a good estimate of it (less than 5% error) irrespective of the 
estimated values of and ~p· 
The remaining parameter ay2 can now be calculated using 
Eq. (4.9). 
Identification Problem #3: 
Parameters identified: T4, Y3h' l3y3' zl3' by5 
Observations required: Experiment #2; plasma FFA concentration 
Maximum 
Error 
M 
15 
30 
Table 5. 
Estimated Values Performance 
c2 Index y2h 
- J/N 
VeT5 ey2 u3p 
3.0 19.77 15.0 0.3 227.23 
2.5 19.80 12.5 0.3 204.26 
2.0 19.85 10.0 0.3 171.40 
1. 5 20.00 7.5 0.3 132.47 + Minimum 
3.0 19.61 15.0 0.3 460.28 
2.5 19.64 12.5 0.3 433,06 
2.0 19.69 10.0 0.3 393.06 
1. 5 19.83 7,5 0.3 342.14 + Minimum 
Estimation of Y2h' 13y2 and u3p . 
True values: Y2h/VeT5 = 21.07 ey2 = 6.o ; u;P = o.4 
Initial guess: Y2h/VeT5 = 10 for M = 15 and 40 for M = 30 
I 
~ 
LU 
I 
-l24-
at t = o,lo,20, ••• ,l20,l30. 
Following the procedure adopted in . identification problem #2 
and referring to Eqs. (4.6) which pertain to identification problem #3, 
we write 
(4.l9) 
where 
s > l.5 
,.., 
P3 = zl3 
p3 = zl3' fasting value of 
= u4i' fasting value of 
,.., 
From simulation studies, the range of p3 was found to be O - 20. 
The parameter by5 is associated with increased FFA oxidation 
due to GH and it is positive. The following substitution was found to 
avoid negative values of by5 in the identification algorithm. 
2 by5 = cr (4.20) 
The range of T4 is limited. Based on simulation studies 
the range of T4 was fowid to be the following: 
20 < T4 < lOO (4.2l) 
The identification problem is the following: 
System: The initial time corresponds to t = O in experi-
ment #2. We have, for 0 ~ t ~ l30 
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(4.22) 
Knowledge of GH input and degradation constants enables us to 
compute u4i(t). If I 4 is the input and K40, ~l and ~O are the 
degradation constants, 
Initial Conditions: 
= F p' fasting plasma FFA level 
= o.o 
u4P(o) = u4P 
u4i (o) = u4i 
Observations: Number of observations, N = 14 
f (t.) = p1 (t.) + 'T)(t.) pc i i i 
ti = O, lO, 20, ••• , 120, 130 
Note that f (o) = p1 (o) = F , assuming noiseless measurement. pc P 
,.., 
Known para.meters: Ve' T5, aY9' t3Y9' P1 
,.., 
Unknown parameters: y3h, f3y3, p3' T4, cr 
14 
Performance index: J = ~ (f (t.) - p1 (t.)}2 L pc i i 
i=l 
(4.23) 
Estimate the unknown parameters so as to minimize J. p1 (t) 
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represents the estimated solution p1(t) using Eqs. (4.22) and (4.23). 
As in identification problem #2, the algorithm starts with 
the largest possible value of p3 and computes ~yP using Eq. (4.19) 
for a given value of The other parameters, and a 
are then identified by the method of quasilinearization. In the initial 
runs the algorithm failed to converge whenever the parameter T4 assumed 
1 
a value outside the range indicated in Eq. (4.21) in any iteration cycle. 
The present procedure circumvents this difficulty by starting the com-
putations with the lowest value of T4. If T4 attains a value outside 
a specified range, it is automatically reset as follows: 
(4.24) 
where ~q4 is the increment in T4 (typically 5 or 10). In order to 
obtain convergence it was found necessary that the specified range of 
T4 should be larger than the one indicated in Eq. (4.21). A range 
20 < T4 < 200 was used in all runs. The rest of the procedure is same 
as in identification problem #2. The results are tabulated in Table 6. 
The parameter values that yield minimum value of J under the condition 
indicated in Eq. (4.21) are chosen as the estimates. 
Remark: The FFA response is more sensitive to y3h and by5 
than to other parameters, and Consequently the estimates 
are better. One encounters the same difficulty as 
in identification problem #2, namely, that the given data do not contain 
enough information to pinpoint more exactly the values of T4, ~yP and 
p3• One way of refining the estimated values of these parameters is to 
l Sometimes negative values were obtained for T4! In such cases the procedure would quickly ''blow-up". 
c3 
3.0 
2.5 
2.0 
Table 6A. 
Estimated Values 
Y3h ,..., 
T4 VeT5 ey3 zl3 
48.32 17.94 0.50 6.9 
35.89 17.98 0.375 8.9 
28.60 18.44 0.30 10.9 
90.24 19.94 o.833 3.9 
70. 74 19.94 0.625 4.9 
48.55 19.94 o.417 6.9 
35.80 18.03 0.313 8.9 
123.83 19.94 1.00 2.9 
70.21 19.92 0.50 4.9 
48.63 19.92 0.333 6.9 
......, 
by5 
--
VeT5 
0.208 
0.208 
0.223 
0.208 
0.207 
0.207 
0.211 
0.207 
0.206 
0.206 
Performance 
Index 
J/N 
88.63 
85.12 
149.59 
88.63 
77.95 
84.14 
106.53 
90.12 
96.65 
103.80 
+ Minimum 
+ Minimum 
(estimated values) 
+ Minimum 
T4 < 100 
Estimation of T4 , y3h, By3 , z13 and by5 . M = 15 
True values: T4 = 60 ; y3h/VeT5 = 17.85 
by5/VeT5 = 0.214 
Initial guess: y3h/VeT5 = 40.0 b_y.5/VeT5 = 
ey3 = o.445 ; z13 = 6.o 
{l.O for c3 = 3.0 0.7 for c3 = 2.5 0.3 for c3 = 2.0 
I 
E 
I 
Estimated Values Performance 
c3 Y3h ~ Index 
T4 VeT5 8y3 - VeT5 J/N zl3 
39.69 18.53 0.50 6.9 0.236 232.65 
3.0 29.45 18.61 0.375 8.9 0.238 225.59 
25.35 19.09 0.30 10.9 0.251 529.28 
101.95 18.54 1.25 2.9 0.236 224.22 
2.5 74.31 18.53 o.833 3.9 0.236 225.49 
58.10 18.53 0.625 4.9 0.236 227.92 
47,32 18.53 0.500 5,9 0.236 229.89 
101.87 18.53 1.00 2.9 0.236 241.96 
2.0 74,38 18.53 o.667 3,9 0.235 230.50 
58.06 18.52 0.50 4.9 0.235 238.80 
Table 6B. Estimation of T4 , y3h, sy3 ' Zi'3 and by5 . M = 30. 
See Table 6A for true values and initial guess. 
+ Minimum 
+ Minimum, T4 < 100 
(estimated values) 
+ Minimum 
I 
~ 
CP 
I 
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make use of the FFA response obtained after IV injection of insulin. rt 
will be recalled that insulin injection is not one among the experiments 
listed earlier (see Page 105) for the identification FFA model para.meters. 
Following infusion in insulin, there is a decrease of FFA release from 
adipose tissue which is countered by epinephrine in the initial stages 
and by GH later. It is therefore possible to refine ~ and ~ para-
meter values associated with FFA release by epinephrine and GH by 
making use of the FFA data taken after an IV dose of insulin, without 
significantly affecting any of the previous results - FFA responses to 
IV ephinephrine and GH. 
Identification problem #4: 
Para.meters identified: T3, YlOh' Ylot' ~yllD z12 
Observations required: Experiment #3; plasma FFA concentration 
at t = 40,50, ••• ,120,130. 
It will be recalled that lipolysis and esterification in 
adipose tissue are assumed to be affected by both interstitial insulin 
concentration and rate in our FFA model. However, the effect of inter-
stitial insulin rate ceases in about 40 minutes by which time the FFA 
response has become almost flat, indicating that the rate of change of 
plasma FFA concentration is close to zero (see Figure ll, 14 and 15). 
Hence the para.meters associated with the effect of interstitial insulin 
concentration on adipose tissue can be identified using the above 
observations. 
Eqs. (4.7) pertain to this identification problem. The initial 
values of are unknown. Designate them by p11, p21 
and p31 respectively. Attempts to arrive at a workable a~orithm that 
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treats plI' p2I and p3I as unknown parameters were not successful. 
In the sequel they are treated as known quantities. is taken to 
be equal to the measured value of the plasma FFA concentration at t = 40. 
Since the FFA response is almost flat by t = 4o, we can take p2I = O. 
Furthermore, by about 40 minutes after the start of the infusion there 
is little difference in the values of p3 ( = z12 ) and inter-
stitial insulin concentration. Hence we can assume p3I = u1i(4o). 
With known initial values of p1, p2 and p3, the identifica-
tion problem is very similar to the preceding one. In fact, the number 
of para.meters to be identified is one less in this case as will become 
evident from the formulation shown below. 
System: The initial time corresponds to t = 40 in experiment 
#3. We have, for 40 ::;; t ::;; 130 
. 
P1 = P2 
Ve(T5P2 + P2)= aylO [l + tanh E~yll (p3 - P3)}] 
(4.25) 
where 
It is assumed that the insulin secretion functions are known 
(see reference 2 for the identification of hormone controller parameters). 
Then u1i(t) can be readily computed using the given glucose data. 
Initial Conditions: 
p1 (o) =Observed value of plasma FFA concentration at 
-l3l-
t = 40 in experiment #3. 
p2(o) = 0.0 
p
3
(o) = Interstitial insulin concentration at t = 40 in 
experiment #3 
Observations: Number of observations, N = lO 
f (t.) =p1 (t.) + T)(t.) pc i i i 
t. = O, lO, 20, ••• , 90, lOO 
1 
Known para.meters: Ve' T5, aY9' t3Y9' Pi 
,.., 
Unknown para.meters: aylO' t3ylO' P3' T3 
lO 
Performance index: J = \ [f (t.) - f>l(t.)} 2 L pc i i 
i=l 
Estimate the unknown para.meters so as to minimize J. p1 (t) 
represents the estimated solution p1 (t) obtained by solving Eqs. (4.25). 
The algorithm is the same as the one used for solving 
identification problem #3. The results are indicated in Table 7 • Since 
the contributions by epinephrine and GH to fasting lipolysis are assumed 
to be negligible in our FFA model (see Page 48), 
ylOh = Basal FFA turnover rate, Y4 
Knowing ylOh and using the relation 
Yiot can be calculated. 
The remaining para.meters associated with the effect of insulin 
on adipose tissue are yllh' t3yll and t12 • They can be readily identi-
fied (identification problem #5) using the FFA data of experiment #3 in 
Estimated Values Performance 
C4 aylO 
Index 
f3yl0 - J/N T3 VeT5 zl2 
30.06 4.38 0.75 8.5 51.34 
3.0 45.02 4.43 0.50 10.5 49.97 
66.30 4.52 0.375 12.5 136.05 
17.12 4.36 1.25 6.5 69.15 
2.5 30.04 4.40 0.625 8.5 43.23 
45.23 4.46 o.417 10.5 80.52 
8.66 4,37 2.00 5.5 64.94 
2.0 17 .01 4.38 1.00 6.5 48.72 
30.06 4.43 0.50 8.5 55,59 
Table 7A. Estimation of T3 , aylO, 8yl0 and zl2 
True values: T3 = 30 aylO/VeT5 = 4.55 
Initial guess: aylO/VeT5 = 14.o 
M = 15. 
+ Minimllln 
+ Minimum 
(estimated values) 
+ Minimum 
8yl0 = · 745 zl2 = 8.5 
I 
t; 
N 
I 
Estimated Values Performance 
C4 a.ylO 
Index 
T3 Sy-10 
,.._ 
J/N 
VeT5 zl2 
17.05 4.35 1. 50 6.5 244.96 
3.0 29.70 4.38 0.75 8.5 230.60 
44.48 4.43 0.50 10.5 280.05 
8.67 4.35 2.50 5,5 250.01 
2.5 16.92 4.36 1.25 6.5 237.62 
29.63 4.40 0.625 8.5 249.51 
8.48 4.36 2.00 5,5 244.86 
2.0 16.79 4.38 1.00 6.5 244.16 
29.66 4.43 0.50 8.5 300.32 
Table 7B. Estimation of T3 , a.ylO' 8ylO and 
-zl2 · M = 30. 
See Table 7A for true values and initial guess. 
+ Minimum 
(estimated values) 
+ Minimum 
+ Minimum 
I 
~ 
w 
I 
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the time interval [0,40] and following the same procedure as in identi-
fication problems 3 and 4. The problem is even simpler since the para-
meter T3 is already known. 
4.5 A Feedback Control Experiment. <82, 83, 84, 58 ) 
One of the questions that is of particular interest to the 
clinicians is the closed-loop control of metabolic systems. How does 
one design a closed-loop control scheme that would maintain the equili-
brium state of a metabolic system despite disturbances acting on it? 
For example, we would like to find out a feedback control law that 
would maintain the plasma glucose level constant when the glucose 
homeostatic system is under the influence of disturbances such as insulin • 
. 
Problems of this nature are being currently investigated in the Physio-
Chemical Automation Research Iaboratory at Cedars-Sinai Medical Center, 
Los Angeles, California. They lead to better quantitative understanding 
of the operation of the glucose regulatory system and provide clues to 
better treatment of insulin-deficient diabetic patients. 
A typical feedback control experiment is the following: The 
subject is given intravenously a dose of insulin sufficient to induce 
significant hypoglycemia. The plasma glucose level is measured con-
tinously using a continuous glucose monitor which gives a proportional 
voltage. An A/D converter converts the analog data into digital data 
{sampled at regular intervals). The latter is processed by a PDP-8/S 
computer to obtain the feedback control policy. At present only glucose 
injection is being considered. A pump that operates on digital data 
(assembled by Digital Logic Corporation, Anaheim, California) is used to 
inject into the subject's blood stream the required amount of glucose. 
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The feedback control law is as follows: 
where 
t 
Ig = Dlgp(t) + D2 gp(t) + D3 ~ 
0 
g (t') dt' p 
Ig = Amount of glucose injected (mg/min) 
(4.26) 
g (t) = Measured value of plasma glucose concentration (de-p 
viation from nominal in mg%) at time t including 
the effect of instrument time constant (approximately 
l minute) 
dg 
gp(t) = ~ 
One of the serious difficulties in the implementation of the 
above scheme is the time delay involved in the measurement of glucose 
concentration. The delay is approximately 4 minutes. This necessitates 
the inclusion of some kind of prediction scheme in the feedback control 
loop. The prediction scheme that is being used at the present time is 
a very simple one, based on a straight line fitted in the least-square 
sense to the last three sampled values of glucose concentration. Let 
t = Current time 
T = Delay 
t:. =Sampling interval 
gl = g at time (t - T) p 
go = g at time (t - T - t:.) p 
g_l = g at time (t - T - 26) p 
Then 
where 
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gp(t) = Predicted value of plasma glucose concentration 
(deviation from nominal in mg%) at time t including 
the effect of instrument time constant 
g (t) = Predicted value of the derivative of plasma glucose p 
concentration at time t 
(4.27) 
Eq. (4.26) becomes 
" t-'f t 
I = Dlgp(t) + aO~pEtF + D3 [ Jg (t')dt' + J g (t')dt'] g 0 p t-'f p (4.28) 
The amount of glucose to be pumped per minute is calculated 
using the above equation at the beginning of every sampling interval. 
However, it is limited by the capacity of the pump (7.5 cc/min for the 
pump used in the Research laboratory at Cedars-Sinai Medical Center) 
and the concentration of the glucose solution. Concentrations upto 
35000 mg% can be used without difficulty. 
permissible value of 
0 s: I g 
I , we have g 
If IgM is the maximum 
(4.29) 
One of the features of the program. that is used to compute 
Ig is that the coefficients D1, D2 and n3 can be changed, if de-
s ired, at any time during the course of the experiment without inter-
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ruption. Furthermore, the feedback loop can be broken and the system 
can be operated open-loop whenever desired. This alJ.ows for any open-
loop control policy that one might wish to execute. For example, it 
may be necessary to pump glucose at the maximum rate in the initial 
stages immediately following the infusion of insulin. A block diagram 
of the feedback control scheme is shown in Figure 24. 
In order to obtain same idea as to the range of values of the 
coefficients n1, D2 and n3 simulation studies of the feedback control 
experiment were conducted using the model of subject 174. Since noisy 
measurements of glucose concentration do not permit a fairly accurate 
prediction of the rate of change of glucose concentration it was decided 
to make n2 = O. n1 and n3 were adjusted by trial and error until satis-
factory results were obtained. They were not altered during the closed-
loop control period, although this is possible in the actual experiment. 
The result is indicated in Figure 25. 
The prediction scheme described earlier makes use of the 
glucose data obtained in the interval [o, t - T] where t is the cur-
rent time and T is the instrmnent delay. It does not make use of the 
information available in the interval [t - T, t], namely, the feedback 
control policy that was adopted. One way of improving the prediction 
scheme is to correct the predicted.value of glucose concentration as 
indicated below, based on the amount of glucose pmnped during the inter-
val [t - T, t]. 
where 
g (t) ~ g (t) + n4A pc P g (4.30) 
g (t) = Predicted-corrected value of plasma glucose concen-pc 
tration (deviation from naminal in m.gi) at time t 
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including the effect of instrument time constant. 
A = Total a.mount of glucose injected in the interval [t - T,t] g 
n4 = Coefficient. 
Fran simuJ.ation studies, the predictor-corrector scheme was 
not found to improve the performance significantly. Hence a further 
improvement was made by linearly weighting the glucose infusion rate 
in the interval [ t - T, t]. ·That is, A was computed as follows: g 
A = ~lf (t - ~F + ~ I (t - 2A) + g g 2 g (4.31) 
where 
~ = Sampling interval 
~lD ~O ••••• =Weighting coefficients 
and 
~l > ~O > ~P ••••••• 
The result obtained using the predictor-corrector scheme with linear 
weighting is indicated in Figure 25. The values of D1 and n3 and 
the open-loop policy were the same as in the previous result with only 
prediction and no correction. Undoubtedly, better results can be ob-
tained by allowing variations in n1 and n3. This means that n1 
and n3 are not really constants but are functions of time. 
The simuJ.ation results give sane idea of the values of the 
"feedback coefficients" and demonstrate how models can be of use in 
answering some questions that arise in clinical studies. 
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Figure 24. Block Diagram of the Feedback Control Scheme. 
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Figure 25. Simulation of Feedback Control Experiment. Deviation of plasma 
glucose concentration includes the effect of instrument time constant and 
delay. T = 3.5 min; 6 = 0.5 min. 
(a) Predictor only. Open-loop policy: Ig = IgM = 2250 mg/min. 
Closed-loop policy: D1 = 40; D2 = O.O; D3 = 30. 
(b) Predictor-corrector with linear weighting. 
Open-loop policy: Ig = IgM = 2250 mg/min. 
Closed-loop policy: D1 = 40; D2 = O; n3 = 30; n4 = 0.75 
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-141-
v. CONCLUSIONS 
There seems to be a lot of confusion about the term model 
since there is no clear-cut definition of the word. Restricting our 
attention to mathematical models, when does a given set of equations 
represent a model? A true model must satisfy the following two require-
ments. First its foundations must be on known laws and established 
facts, physical, chemical or physiological as the case may be. Secondly 
it must have predictive capabilities. This implies that if the parameters 
of the model were picked to fit the data from, let us say, two different 
experiments performed under identical conditions, then without altering 
the parameter values it should be possible to reproduce the data from a 
third experiment performed under the same conditions as the first two. 
It is assumed, of course, that we have a well-defined acceptable criterion 
for comparison of experimental and simulated data. 
The validity of the proposed model was based on glucose, in-
sulin and FFA responses following IV administration of either glucose 
or insulin in a s :i.ngle dose. The ability of the model to reproduce 
responses to IV infusions of glucagon, epinephrine, GH and combinations 
of glucose and insulin needs to be tested. It must be emphasized that 
all the necessary data must be obtained from experiments performed on 
the~ individual starting from the~ initial conditions. It is 
important to test how well the proposed model can reproduce responses to 
various stimuli before considering inclusion of oral and stress inputs 
and neglected portions such as TG and amino acid loops. This will un-
doubtedly suggest improvements - inclusion of other possible stimuli for 
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secretion of insulin, for example. 
Provision for oral and stress inputs and inclusion of TG, 
ketones, glycerol, lactic and pyruvic acids, amino acids, glucocorticoids 
and thyroxin are obvious extensions of the proposed model. Models for 
the metabolism of the above substrates and hormones are briefly dis-
cussed here. 
Model for TG metabolism: The term TG here refers to endo-
genous triglycerides1 contained in very low-density or pre-~ lipoproteins 
(see Appendix). 2 It is canmonly known as VLDL-TG • The source of this 
endogenous TG is liver. Plasma FFA entering the liver are partly oxidized 
and partly converted into TG which are either stored or released into 
plasma. Tracer studies and compartment analyses have indicated that 
the hepatic TG pool is nonhamogeneous and that only a small portion of 
newly synthesized hepatic TG is delivered to the plasma, the rest being 
stored temporarily in an intrahepatic "sink"~pRI 7) Normal fasting 
plasma concentration of TG varies with age~US F It is about 70 mft'/o in 
normal adults of age 20-40 years. The fasting turnover rate is about 
15 mg/min in healthy individuals~pRF 
The model for TG metabolism is shown in Figure 26. The vari-
able y7 is the amount of FFA taken up by the liver for synthesis and 
release of TG. The delay element3 accounts for the delay in the appear-
l 
2 
3 
Chylomicrons which are rich in TG are exogenollil since they are 
derived fran dietary fat during absorption. 
VLDL, pre-~ and a2 are synonymous • 
Pure time delay is not one among the basic building blocks shown 
in Figure 10. 
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ance of newly synthesized 'IU in plasma following FFA uptake by the liver. 
T is about 10 minutes~ S F ~ is the conversion factor and s is the 
derivative operator ~t • It should be noted that the saturation effects 
have already been included in the FFA model. 
The endogenous 'IU released by the liver are taken _up by muscle 
and adipose tissue. The transport of 'IU across the cell membrance has 
not been clearly understood. First of all, the 'IU undergo hydrolysis 
releasing FFA and glycerol (see Figure 6). It is not yet known just 
where between the vascular surface and intracellular 'IU this hydrolysis 
takes place~UTF The FFA are taken up by the target tissues and are re-
esterified into 'IU. The glycerol fraction is carried to the liver. A 
fraction of the 'IU may be taken up intact without prior hydrolysis. 
Taking the evidence of both in vitro and in vivo experiments, Shapiro(BB) 
concludes that uptake of 'IU by adipose tissue may be facilitated by both 
partial and complete hydrolysis and resynthesis. 
The utilization or degradation of 'IU is represented in our 
'IU model by a para.meter-dependent saturation-type nonlinearity, based 
on the suggestion by Reaven et.al.(B9) for concentration versus turnover 
rate. It is assumed to be enhanced by plasma insulin concentration~9MF 
Due to hydrolysis of 'IU both in the vascular space and at the cell 
membrane of the target organs, an increased utilization of 'IU would be 
expected to increase the plasma concentrations of both FFA and glycerol. 
In fact, several authors have elevated plasma FFA concentrations in man 
by infusion of Dfr~9lI9O F This points to the coupling of 'IU model with 
FFA and glycerol models. It is indicated in Figure 26. 
Model for ketone metabolism: The plasma level of ketones -
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acetoacetic and ~-hydroxybutyric acids - is about l mg"/o in healthy in-
dividuals under normal fasting conditions~lpF It increases significantly 
after l8-24 hours of fasting~9P I PoF The s~gested model for the metab-
olism of ketones is depicted in Figure 27. From our model for FFA 
metabolism, y8 µEq/min of FFA are taken up by the liver for oxidation 
and production of ketone bodies. Since the nonlinear effects have al-
ready been taken into account in the FFA model, a constant relates Yg 
to the release rate by the liver. Only a fraction of Ys is converted 
into ketones, the rest being completely oxidized to co2 and H20. Ketone 
production results also from the so-called ketogenic amino acids. The 
process can be represented by a nonlinearity of saturation-type. 
There are two utilization pathways for ketones, both of which 
depend on their plasma concentration. (i) Peripheral utilization, 
chiefly by muscle and (ii) Urinary excretion. Ketones are normally 
metabolized as rapidly as they are formed~lpF Increased production leads 
to ketosis, i.e., accumulation of ketone bodies in plasma. It indicates 
that the ability of the tissues to oxidize ketones has been exceeded. 
Thus a nonlinearity of saturation-type seems appropriate for represent-
ing peripheral utilization. The functional relationships between plasma 
concentration and urinary excretion of acetoacetic and ~-hydroxybutyric 
acids in normal humans have been reported by Galvin etKal~94 F 
Model for glycerol metabolism: The fasting concentration of 
plasma glycerol is about 35 mmoles/mt and the turnover rate is about 
0.30 mmoles/min in normal subjects~ OR F The s~gested model for glycerol 
metabolism is shown in Figure 28. Glycerol release from adipose tissue 
is assumed to be proportional to FFA release (y1 + y2 + y3) in our 
Yg 
·I µEq/min) CONSTANT Ketone Rate mg mlll ~"-
·I Ketogenic 
amlllo aci s 
KETONE PRODUCTION 
FROM AMINO ACIDS I (mg/min 
DISTRIBUTION 
Ketone Rate 
(mg/min) 
I J 
PERIPHERAL 
UTILIZATION 
URINARY 
EXCRETION 
Figure 27. Model for Ketone Metabolism. yR - Liver uptake of FFA for 
oxidation and ketone production (from FFA model). 
Plasma l Ketone Cone I (mg%) • 
I 
~ 
0\ 
I 
FFA Rate TV Glycerol 
(yl + Y2 + Y3l I rfycerol Rate A mmoles /min CONSTANT (mmoles /min (µEq/min) ._ 
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+r-TG Rate 
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Figure 28. Model for Glycerol Metabolism 
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model. In addition there is contribution from hydrolysis of VLDL-'IG 
(see Figure 2.6). Data of Senior and Loridan(95) suggest a simple linear 
representation for glycerol distribution and degradation. They found 
intravenously administered glycerol to disappear with a half-life of 
approximately 4o minutes. 
Model for lactic and pyruvic acid metabolism: The lactic acid 
level in blood ranges from lO to l5 mg% under resting conditions; whereas 
the amounts of pyruvic acid normally found do not exceed l mg%. The 
normal plasma concentration of pyruvic acid is thus only one tenth or 
one twentieth that of lactic acid~lPF Reichard et.al. (96) have estim-
ated a lactate1 turnover rate of about 22 to 24 mg/kg/hr in normal 
humans under resting conditions. Brain contributes about 5Cf/o of this, 
the balance being from the musculature. A constant rate of production 
of lactic acid by the brain would be expected since it utilizes glucose 
at a steady rate under most circumstances. Exercise, stress and infusion 
of catecholamines enhance the production of lactic and pyruvic acids 
by muscle by increasing glycogen breakdown and subsequent g]¥colysis. 
A model for the metabolism of lactic and pyruvic acids that 
is based upon the above considerations is indicated in Figure 29. Pro-
duction by muscle can be represented by a saturation-type nonlinearity. 
As in the case of glycerol model, distribution and degradation is re-
presented by a simple linear model. Uptake by liver is the most import-
ant utilization pathway for lactic and pyruvic acids. A small fraction 
is excreted in the urine and sweat which has been neglected in the sug-
l A salt of lactic acid. 
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L & P Rate 
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+ 
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Figure 29. Model for Lactic and Pyruvic Acid Metabolism. 
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gested model. 
Model for amino acid metabolism: There are 10 essential amino 
acids in man and they do not all behave the same way. They can be 
broadly classified into two groups, viz., ketogenic and glucogenic. 
Leucine, isoleucine, phenylalanine and tyrosine are said to be ketogenic 
because they are converted to the ketone body, acetoacetic acid. Glu-
cogenic or gluconeogenic amino acids such as threonine, valine and many 
others give rise to compounds that can readily be converted into glucose. 
A highly simplified model for amino acid metabolism, construct-
ed along the lines of the proposed FFA model in Figure 30. There are two 
pathways of utilization - liver uptake and extrahepatic tissue uptake, 
chiefly muscle. Glucocorticoids and throxin stimulate protein catabolism 
and thus increase the level of amino acids in plasma. GH and insulin 
produce the opposite effect. Glucagon decreases the level of plasma 
amino acids by primarily enhancing the hepatic utilization~9TI9pF 
The lumped representation of glucoenegenesis in the proposed 
model for FFA-glucose metabolism can now be refined as indicated in 
Fi{?;ure 31 to include the effects of amino acids, lactic and pyruvic 
acids and glycerol. 
Models for glucocorticoids and thyroxin can be based on the 
work reported in the literature~99IlllF A simple one-compartment 
model similar to that of glucagon is suggested for the metabolis.m of 
glucocorticoids. A line'l,r model similar to that proposed for epinephrine 
is a good representation for the distribution and degradation mechanism 
of norepinephrine; however, the secretion of norepinephrine is somewhat 
more difficult to model since it is a neurohumor. 
Glucocorticoids 
OXl.ll 
PROTEIN 
CATABOLISM 
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Figure 30. A Simplified Model for Metabolism of Amino 
Acids. AA - Amino acids. 
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5.2. Concluding Remarks. 
A mathematical model in terms of nonlinear ordinary differential 
equations for the control mechanism of FFA-glucose metabolism in normal 
humans was presented. Modeling was approached from a systems viewpoint. 
The model was comprised of integrators, first-order lage and saturation-
type nonlinearities that are inherent in metabolic systems. It was con-
structed in such a way that additions such as amino acid and 1'G portions 
are possible without destroying its basic structure. It can be repre-
sented in the form: 
where 
z = f(z, u, v) 
u = g(z, z, u) 
z = (15 x 1) metabolic state vector 
u = (4 x 1) hormonal control vector 
v = (5 x l) input vector comprising of glucose and hormone 
inputs (intravenous) 
Ample evidence was produced justif'ying the physiological basis of the 
model. Methods were suggested for systematically identifying the para-
meters of the FFA model. Although the model did not adequate:cy- reprod-
uce the finer details of the actual responses in same instances, the 
limited success supports the. approach. Inclusion of the remaining 
hormonal controls and refinements of mathematical relationships, as 
suggested by studies on specific portions of the model, would undoubted:cy-
yield better results. 
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APPENDIX 
SUMMARY OF LIPIBS IN PI.ASMA 
Lipids are organic compotmds which are insoluble in chloroform, 
ether or benzene. Ingested lipid contains chiefly triglycerides. After 
digestion they appear in the intestinal J..ymph as an emulsion of cbylo-
microns. The presence of cbylomicrons causes, usually about 2-3 hours 
after meals, milkiness (lactescence) in the blood plasma; this is termed 
alimentary lipemia. It is cleared by the action of the clearing factor 
a substance now known to be the enzyme lipoprotein lipase. Chylomicrons 
are the largest lipid-bearing particles in plasma, containing more than 
8Cfl/o of triglycerides. They have the lowest density. 
In addition to cbylomicrons blood plasma contains lipids that 
are formed endogenously - phospholipids such as lecithin and chephalin, 
free chlesterol, chlesterol esters and free fatty acids. All lipids in 
plasma are associated with 'Protein in some form of binding. The density of 
the various lipid-protein complexes in circulation varies with the amount 
of lipid and the a.mount of protein they contain, and on this basis they 
a.re divided into very low-density, low-density and high-density fract-
ions, known respectively as pre-~I ~ and a lipoproteins. Since lipo-
proteins have a lower density than other serum proteins, they float to 
the surface in the ultracentrifuge and the rate of floatation can be 
measured. This rate is called the Sf value. 
The Sf value, density, approximate plasma concentration and 
composition of cbylomicrons and lipoproteins are given in the following 
table ~ 4S F 
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Chylomicrons Pre-t3 t3 a Lipoproteins Lipoproteins Lipoproteins 
sf value > lOOO lO-lOOO 0-lO -
Density 
< l.006 l.006 - l.Ol9 - l.063 -(gm/mt) l.Ol9 l.063 l.2l0 
Plasma Cone. 0 - 200 l25 300 350 
(mg%) 
Components Per Cent 
Triglyceride 8l 52 9 8. 
Phospholipid 7 l8 23 26 
Free Chlesterol 
Chlesterol esters } 9 22 47 l9 
Protein 2 7 2l 46 
Table 8. Density, concentration and composition 
of plasma lipids. 
Free fatty acids are long chain fatty acids and in man they 
are chiefly oleic acid (45%), palmitic acid (25%), stearic acid (lofo) 
with others in small a.mounts. They are complexed with albumin in blood 
plasma. The word "free" here means "unesterified" or "nonesterified". 
The FFA-albumin complexes contain 0.5% of FFA, 0.5% of phospholipids 
and 9<J'/o of albumin. They are formed immediately when fatty acids are 
released into the blood stream and they release their fatty acids at 
sites of utilization. The affinity of albumin for fatty acids is quite 
specific. When bound to albumin, the fatty acids are soluble in water. 
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